Irene Wapnir, MD

4.7/5

65 Patient Ratings

175 Patient Reviews

Irene Wapnir, MD

Surgical oncologist, Breast surgeon, Breast specialist

Professor of Surgery (General Surgery)

View Professional Summary

Additional Languages Spoken:

Spanish

Insurance Coverage

Online Second Opinion Program

Resources for Referring Physicians

Biography

Dr. Wapnir’s work in the field of breast oncology spans clinical and translational research. Her past bench research centered on elucidating the activity of the sodium iodide symporter in lactation and breast cancer. She conducted studies on the impact of breast cancer locoregional recurrences with colleagues from the NSABP (NRG Oncology) Cooperative Oncology Group. Based on these, she co-chaired the CALOR (Chemotherapy for isolated locoregional recurrence of breast cancer) trial, that has since defined the use of systemic therapies for this patient population. Nationally, she has been continuously engaged in clinical trials as a member of the NRG Breast Locoregional Subcommittee and NCI-BOLD Task Force.

Dr Wapnir’s efforts focus on extending therapeutic options and advancing the treatment of breast cancer. As such, she designed a novel randomized clinical trial at Stanford, to test the effectiveness of neoadjuvant partial breast irradiation followed by delayed lumpectomy surgery for women with ductal carcinoma in situ (NORDIS: NeOadjuvant Radiation of Ductal Carcinoma In Situ) [https://med.stanford.edu/cancer/trials/results.html?ctid=NCT03909282&conditionId=&serviceLineId=Cancer&condition=]. Other institutional investigator-initiated studies she has pioneered range from understanding skin perfusion patterns in mastectomy flaps to improve outcomes in nipple sparing mastectomies and safeguard against ischemic complications to the efficacy of black ink tattooing as a technique for marking of biopsied axillary lymph nodes. Together with Dr. Dung Nguyen, she has devised an innovative approach for breast reconstruction, creating a biological implant based on omental free flaps and fat-grafting [https://scopeblog.stanford.edu/2019/12/02/stanford-surgeons-innovate-new-biological-breast-implants/], providing patients with a unique alternative for mastectomy reconstruction.

Additional unique clinical studies and services she is leading institutionally include:
(1) Pivotal trial, using fluorescent based technology to detect residual breast cancer in the lumpectomy cavity [https://med.stanford.edu/cancer/trials/results.html?ctid=NCT03686215&conditionId=&serviceLineId=Cancer&condition=].
(2) Immune-stimulating local treatments for inoperable, metastatic breast cancer (Melinda Telli, MD, PI) to activate a systemic immune response.

View Full Biography

Professional Summary

Education & Certifications

Fellowship: Rutgers Robert Wood Johnson Breast Surgery Fellowship (1988) NJ
Residency: Lincoln Medical and Mental Health Center General Surgery Residency (1985) NY
Internship: Lincoln Medical and Mental Health Center General Surgery Residency (1981) NY
- Board Certification: American Board of Surgery, General Surgery (1986)
- Medical Education: Universidad Autonoma Metropolitana (1980) Mexico
- MD, Universidad A. Metropolitana, Medicine (1980)
- BA, Goucher College, Biological Sciences (1975)

View More Education & Certifications

Honors & Awards

Awards Committee, Assoc Women Surgeons (2004-2010)
National Cancer Institute BOLD Task Force, NCI- Breast Oncology Locoregional Disease Task Force (2018-present)
Protocol Chair Breast Cancer Local Recurrence Trial, NSABP/NRG (2006-2010)
- Publications Committee, American Society of Breast Surgeons (2010-2013)
- SSO-ASTRO-ASCO Consensus Guideline On Margins for Ductal carcinoa in situ, Margins Panel on DCIS Margins (2015)
- The Maastricht Breast Cancer Endpoint Consensus Group, Maastricht Breast Cancer Endpoint Consensus Group (2013)
- Visiting Scholar, Ben Gurion University of the Negev, Israel (2012)
- Working Group Breast Committee, NSABP/NRG (2000- present)

View More Honors & Awards

Memberships

Editorial Board, Annals of Surgical Oncology (2017 - 2021)

Administrative Appointments

Chief of Breast Surgery, Section of Surgical Oncology (2005 - 2019)

Publications

Subtle differences in quality of life after breast cancer surgery
Wapnir, I. L., Cody, R. P., & Greco, R. S. (1999). Subtle differences in quality of life after breast cancer surgery. ANNALS OF SURGICAL ONCOLOGY, 6(4), 359–366.
The mammary gland iodide transporter is expressed during lactation and in breast cancer
Tazebay, U. H., Wapnir, I. L., Levy, O., Dohan, O., Zuckier, L. S., Zhao, Q. H., … Carrasco, N. (2000). The mammary gland iodide transporter is expressed during lactation and in breast cancer. NATURE MEDICINE, 6(8), 871–878.
The inverse relationship between microvessel counts and tumor volume in breast cancer.
Wapnir, I. L., Barnard, N., Wartenberg, D., & Greco, R. S. (2001). The inverse relationship between microvessel counts and tumor volume in breast cancer. Breast Journal, 7(3), 184–188.
- Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections
  Wapnir, I. L., van de Rijn, M., Nowels, K., Amenta, P. S., Walton, K., Montgomery, K., … Carrasco, N. (2003). Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 88(4), 1880–88.
- MAGNESIUM-METABOLISM IN EXPERIMENTAL DIABETES-MELLITUS
  Fort, P., Lifshitz, F., Wapnir, I. L., & Wapnir, R. A. (1977). MAGNESIUM-METABOLISM IN EXPERIMENTAL DIABETES-MELLITUS. DIABETES, 26(9), 882–886.
- Elephantiasic prefibial myxedema
  Cohen, J. B., Balzer, B., Wapnir, I., & McDougall, I. R. (2004). Elephantiasic prefibial myxedema. THYROID, 14(3), 237–38.
- The Na+/I- symporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid
  Wapnir, I. L., Goris, M., Yudd, A., Dohan, O., Adelman, D., Nowels, K., & Carrasco, N. (2004). The Na+/I- symporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid. CLINICAL CANCER RESEARCH, 10(13), 4294–4302.
- Magnetic resonance imaging of suspicious breast masses seen on one mammographic view.
  Offodile, R. S., Daniel, B. L., Jeffrey, S. S., Wapnir, I., Dirbas, F. M., & Ikeda, D. M. (2004). Magnetic resonance imaging of suspicious breast masses seen on one mammographic view. Breast Journal, 10(5), 416–22.
- Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five national surgical adjuvant breast and bowel project node-positive adjuvant breast cancer trials
  Wapnir, I. L., Anderson, S. J., Mamounas, E. P., Geyer, C. E., Jeong, J. H., Tan-Chiu, E., … Wolmark, N. (2006). Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five national surgical adjuvant breast and bowel project node-positive adjuvant breast cancer trials. JOURNAL OF CLINICAL ONCOLOGY, 24(13), 2028–37.
- Bioluminescent-inescent monitoring of NIS-mediated I-131 ablative effects in MCF-7 Xenografts
  Ghosh, M., Gambhir, S. S., De, A., Nowels, K., Goris, M., & Wapnir, I. (2006). Bioluminescent-inescent monitoring of NIS-mediated I-131 ablative effects in MCF-7 Xenografts. MOLECULAR IMAGING, 5(2), 76–84.
- Expression of the Na+/I- symporter (NIS) is markedly decreased or absent in gastric cancer and intestinal metaplastic mucosa of Barrett esophagus
  Altorjay, A., Dohan, O., Szilagyi, A., Paroder, M., Wapnir, I. L., & Carrasco, N. (2007). Expression of the Na+/I- symporter (NIS) is markedly decreased or absent in gastric cancer and intestinal metaplastic mucosa of Barrett esophagus. BMC CANCER, 7.
- Resolution of hypoalbuminemia after excision of malignant phyllodes tumor
  Samiian, L., Daniel, B., & Wapnir, I. (2006). Resolution of hypoalbuminemia after excision of malignant phyllodes tumor. CLINICAL BREAST CANCER, 7(5), 411–12.
- Egg retrieval with cryopreservation does not delay breast cancer treatment
  Madrigrano, A., Westphal, L., & Wapnir, I. (2007). Egg retrieval with cryopreservation does not delay breast cancer treatment. AMERICAN JOURNAL OF SURGERY, 194(4), 477–81.
- Metastases to the breast: Alveolar soft part sarcoma in adolescents
  Madrigrano, A., Beach, B., Wheeler, A., & Wapnir, I. (2008). Metastases to the breast: Alveolar soft part sarcoma in adolescents. CLINICAL BREAST CANCER, 8(1), 92–93.
- A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37
  Wapnir, I. L., Aebi, S., Geyer, C. E., Zahrieh, D., Gelber, R. D., Anderson, S. J., … Wolmark, N. (2008). A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37. CLINICAL BREAST CANCER, 8(3), 287–92.
- Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a Prospective Randomized Trial Evaluating Chemotherapy after Local Therapy for Isolated Locoregional Recurrences of Breast Cancer
  Wapnir, I. L., Aebi, S., Gelber, S., Anderson, S. J., Lang, I., Robidoux, A., … Wolmark, N. (2008). Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a Prospective Randomized Trial Evaluating Chemotherapy after Local Therapy for Isolated Locoregional Recurrences of Breast Cancer. ANNALS OF SURGICAL ONCOLOGY, 15(11), 3227–31.
- Leiomyosarcoma of the breast in a patient with a 10-year-history of cyclophosphamide exposure: a case report.
  De la Pena, J., & Wapnir, I. (2008). Leiomyosarcoma of the breast in a patient with a 10-year-history of cyclophosphamide exposure: a case report. Cases Journal, 1(1), 301-?
- Endogenous NIS Expression in Triple-Negative Breast Cancers
  Renier, C., Yao, C., Goris, M., Ghosh, M., Katznelson, L., Nowles, K., … Wapnir, I. (2009). Endogenous NIS Expression in Triple-Negative Breast Cancers. ANNALS OF SURGICAL ONCOLOGY, 16(4), 962–68.
- Association of reactive oxygen species levels and radioresistance in cancer stem cells
  Diehn, M., Cho, R. W., Lobo, N. A., Kalisky, T., Dorie, M. J., Kulp, A. N., … Clarke, M. F. (2009). Association of reactive oxygen species levels and radioresistance in cancer stem cells. NATURE, 458(7239), 780–U123.
- Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Patients Treated by Breast-Conserving Therapy in Five National Surgical Adjuvant Breast and Bowel Project Protocols of Node-Negative Breast Cancer
  Anderson, S. J., Wapnir, I., Dignam, J. J., Fisher, B., Mamounas, E. P., Jeong, J.-H., … Wolmark, N. (2009). Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Patients Treated by Breast-Conserving Therapy in Five National Surgical Adjuvant Breast and Bowel Project Protocols of Node-Negative Breast Cancer. JOURNAL OF CLINICAL ONCOLOGY, 27(15), 2466–73.
- Breast cancer brain metastases express the sodium iodide symporter
  Renier, C., Vogel, H., Offor, O., Yao, C., & Wapnir, I. (2010). Breast cancer brain metastases express the sodium iodide symporter. JOURNAL OF NEURO-ONCOLOGY, 96(3), 331–36.
- Timing of Breast Cancer Treatments with Oocyte Retrieval and Embryo Cryopreservation
  Baynosa, J., Westphal, L. M., Madrigrano, A., & Wapnir, I. (2009). Timing of Breast Cancer Treatments with Oocyte Retrieval and Embryo Cryopreservation. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 209(5), 603–7.
- In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
  Brody, J. D., Ai, W. Z., Czerwinski, D. K., Torchia, J. A., Levy, M., Advani, R. H., … Levy, R. (2010). In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study. JOURNAL OF CLINICAL ONCOLOGY, 28(28), 4324–32.
- KT5823 Differentially Modulates Sodium Iodide Symporter Expression, Activity, and Glycosylation between Thyroid and Breast Cancer Cells
  Beyer, S., Lakshmanan, A., Liu, Y.-yu, Zhang, X., Wapnir, I., Smolenski, A., & Jhiang, S. (2011). KT5823 Differentially Modulates Sodium Iodide Symporter Expression, Activity, and Glycosylation between Thyroid and Breast Cancer Cells. ENDOCRINOLOGY, 152(3), 782–92.
- Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS
  Wapnir, I. L., Dignam, J. J., Fisher, B., Mamounas, E. P., Anderson, S. J., Julian, T. B., … Wolmark, N. (2011). Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 103(6), 478–88.
- Eusorbents and Eusorption: A Review of Physiological Events to Therapeutic Concepts
  Wapnir, R. A., Wapnir, I., & Lifshitz, F. (2011). Eusorbents and Eusorption: A Review of Physiological Events to Therapeutic Concepts. JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, 30(1), 1–10.
- A REAPPRAISAL OF PROPHYLACTIC MASTECTOMY
  Wapnir, I. L., Rabinowitz, B., & Greco, R. S. (1990). A REAPPRAISAL OF PROPHYLACTIC MASTECTOMY. SURGERY GYNECOLOGY & OBSTETRICS, 171(2), 171–184.
- Integration and safety of fertility preservation in a breast cancer program
  Westphal, L. M., & Wapnir, I. L. (2012). Integration and safety of fertility preservation in a breast cancer program. GYNECOLOGIC ONCOLOGY, 124(3), 474–76.
- The diagnostic value of nipple discharge cytology: Breast imaging complements predictive value of nipple discharge cytology
  Kalu, O. N., Chow, C., Wheeler, A., Kong, C., & Wapnir, I. (2012). The diagnostic value of nipple discharge cytology: Breast imaging complements predictive value of nipple discharge cytology. JOURNAL OF SURGICAL ONCOLOGY, 106(4), 381–85.
- MRI Enhancement Correlates With High Grade Desmoid Tumor of Breast
  Kim, M. J. J., Wapnir, I. L., Ikeda, D. M., Chisholm, K. M., Do, Y., & Daniel, B. L. (2012). MRI Enhancement Correlates With High Grade Desmoid Tumor of Breast. BREAST JOURNAL, 18(4), 374–76.
- Outcomes of Partial Mastectomy in Male Breast Cancer Patients: Analysis of SEER, 1983-2009
  Cloyd, J. M., Hernandez-Boussard, T., & Wapnir, I. L. (2013). Outcomes of Partial Mastectomy in Male Breast Cancer Patients: Analysis of SEER, 1983-2009. ANNALS OF SURGICAL ONCOLOGY, 20(5), 1545–50.
- Poor compliance with breast cancer treatment guidelines in men undergoing breast-conserving surgery.
  Cloyd, J. M., Hernandez-Boussard, T., & Wapnir, I. L. (2013). Poor compliance with breast cancer treatment guidelines in men undergoing breast-conserving surgery. Breast Cancer Research and Treatment, 139(1), 177–82.
- COMPARTMENT SYNDROME IN COMBINED ARTERIAL AND VENOUS INJURIES OF THE LOWER-EXTREMITY
  Shah, P. M., Wapnir, I., Babu, S., Stahl, W. M., & CLAUSS, R. H. (1989). COMPARTMENT SYNDROME IN COMBINED ARTERIAL AND VENOUS INJURIES OF THE LOWER-EXTREMITY. AMERICAN JOURNAL OF SURGERY, 158(2), 136–141.
- PORTAL-VEIN INJURIES - NONINVASIVE FOLLOW-UP OF VENORRHAPHY
  Ivatury, R. R., NALLATHAMBI, M., LANKIN, D. H., Wapnir, I., Rohman, M., & Stahl, W. M. (1987). PORTAL-VEIN INJURIES - NONINVASIVE FOLLOW-UP OF VENORRHAPHY. ANNALS OF SURGERY, 206(6), 733–737.
- NONOPERATIVE MANAGEMENT VERSUS EARLY OPERATION FOR BLUNT SPLENIC TRAUMA IN ADULTS
  NALLATHAMBI, M. N., Ivatury, R. R., Wapnir, I., Rohman, M., & Stahl, W. M. (1988). NONOPERATIVE MANAGEMENT VERSUS EARLY OPERATION FOR BLUNT SPLENIC TRAUMA IN ADULTS. SURGERY GYNECOLOGY & OBSTETRICS, 166(3), 252–258.
- ASYMMETRICAL BREASTS IN AN ADOLESCENT
  Wapnir, I., Rabinowitz, B., & Snyderman, R. (1988). ASYMMETRICAL BREASTS IN AN ADOLESCENT. PLASTIC AND RECONSTRUCTIVE SURGERY, 81(5), 813–813.
- PYOGENIC SPLENIC ABSCESS IN INTRAVENOUS DRUG-ADDICTION
  NALLATHAMBI, M. N., Ivatury, R. R., LANKIN, D. H., Wapnir, I. L., & Stahl, W. M. (1987). PYOGENIC SPLENIC ABSCESS IN INTRAVENOUS DRUG-ADDICTION. AMERICAN SURGEON, 53(6), 342–346.
- [Gastroesophageal reflux in children. Experience in 100 cases treated by Nissen's fundoplication].
  Pérez-Fernández, L., Peña-Rodríguez, A., & Wapnir, I. (1985). [Gastroesophageal reflux in children. Experience in 100 cases treated by Nissen's fundoplication]. Boletín Médico Del Hospital Infantil De México, 42(4), 256–265.
- LATENT MAMMARY TUBERCULOSIS - A CASE-REPORT
  Wapnir, I. L., PALLAN, T. M., Gaudino, J., & Stahl, W. M. (1985). LATENT MAMMARY TUBERCULOSIS - A CASE-REPORT. SURGERY, 98(5), 976–978.
- COLLAGEN-INDUCED MMP-2 ACTIVATION IN HUMAN BREAST-CANCER
  Thompson, E. W., Yu, M., Bueno, J., Jin, L., Maiti, S. N., PALAOMARCO, F. L., … Azzam, H. (1994). COLLAGEN-INDUCED MMP-2 ACTIVATION IN HUMAN BREAST-CANCER. BREAST CANCER RESEARCH AND TREATMENT, 31(2-3), 357–370.
- Mammographic changes following biopsy and lumpectomy-breast irradiation.
  Wapnir, I. L., Alden-Corbett, S., Zicherman, B., & Greco, R. S. (1993). Mammographic changes following biopsy and lumpectomy-breast irradiation. New Jersey Medicine : the Journal of the Medical Society of New Jersey, 90(1), 55–59.
- Three dimensional staging of breast cancer
  Wapnir, I. L., WARTENBERG, D. E., & Greco, R. S. (1996). Three dimensional staging of breast cancer. BREAST CANCER RESEARCH AND TREATMENT, 41(1), 15–19.
- Collagen gene expression in the neomatrix of carcinoma of the breast
  Wapnir, I. L., Southard, H., Chen, G. H., Friedman, J., BOYD, C. D., & Amenta, P. S. (1996). Collagen gene expression in the neomatrix of carcinoma of the breast. INVASION & METASTASIS, 16(6), 308–316.
- Local recurrence after breast conservation
  Local recurrence after breast conservation. (1996). Current Surgery, 53(161).
- Pathologic differences in nonpalpable breast cancers detected by xeromammography and film screen mammography
  Pathologic differences in nonpalpable breast cancers detected by xeromammography and film screen mammography. (1996). Breast Disease, 9(4).
- The verbal abuse of resident physicians
  The verbal abuse of resident physicians. (1999). Disease Management and Clinical Outcomes, 1(6).
- Residual tumor and breast biopsy margins
  Residual tumor and breast biopsy margins. (1989). Breast Disease, 2.
- Superior quality of life following lumpectomy-axillary dissection in patients with stage I and stage II beast cancer
  Superior quality of life following lumpectomy-axillary dissection in patients with stage I and stage II beast cancer. (1996). Surgical Forum, XLVII.
- Stage II ductal carcinoma arising in a fibroadenoma
  Stage II ductal carcinoma arising in a fibroadenoma. (1995). Breast Disease, 8.
- Muerte inesperada y sindrome de muerte subita en la infancia
  Muerte inesperada y sindrome de muerte subita en la infancia. (1980). PAtologia (Mexico), 18.
- Development of a breast cancer brain metastases model to study I-131 radioablative therapy.
  Renier, C., De, A., Hou, L., Dunkel, J., Sun, A., Prugpichailers, T., … Wapnir, I. L. (2009). Development of a breast cancer brain metastases model to study I-131 radioablative therapy. CANCER RESEARCH, 69(2), 159S–160S.
- New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients
  Kohrt, H., Olshen, R., Bermas, H., GOODSON, W., Henry, S., Rouse, R., … JEFFREY, S. (2008). New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BREAST CANCER RESEARCH AND TREATMENT, 109(3), 588–88.
- Determining Adequate Nipple Areolar Complex Perfusion in Breast Cancer Related Mastectomies
  Kieryn, A., Dua, M., Paro, J., Meyer, S., Gurtner, G., & Wapnir, I. (2012). Determining Adequate Nipple Areolar Complex Perfusion in Breast Cancer Related Mastectomies. Presented at the 65th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO), ORLANDO,FL,FL,FL,FL: SPRINGER.
- The effect acute sleep deprivation experienced in a simulated on-call period on surgical performance
  Woo, R. K., Greco, R. S., Wapnir, I. L., & Colrain, I. M. (2004). The effect acute sleep deprivation experienced in a simulated on-call period on surgical performance. Presented at the 18th Annual Meeting of the Associated-Professional-Sleep-Societies, PHILADELPHIA,PA,PA,PA,PA: AMER ACAD SLEEP MEDICINE.
- The Fate of DCIS After Neoadjuvant Treatment for Invasive Breast Cancer
  Porter, C., Morrison, D., & Wapnir, I. (2013). The Fate of DCIS After Neoadjuvant Treatment for Invasive Breast Cancer. Presented at the 14th Annual Meeting of the American-Society-of-Breast-Surgeons, CHICAGO,IL,IL,IL,IL: SPRINGER.
- Intraoperative imaging of nipple perfusion patterns and ischemic complications in nipple-sparing mastectomies.
  Wapnir, I., Dua, M., Kieryn, A., Paro, J., Morrison, D., Kahn, D., … Gurtner, G. (2014). Intraoperative imaging of nipple perfusion patterns and ischemic complications in nipple-sparing mastectomies. Annals of Surgical Oncology, 21(1), 100–106.
- Ex vivo Evans blue assessment of the blood brain barrier in three breast cancer brain metastasis models.
  Do, J., Foster, D., Renier, C., Vogel, H., Rosenblum, S., Doyle, T. C., … Wapnir, I. (2014). Ex vivo Evans blue assessment of the blood brain barrier in three breast cancer brain metastasis models. Breast Cancer Research and Treatment, 144(1), 93–101.
- Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial
  Aebi, S., Gelber, S., Anderson, S. J., Lang, I., Robidoux, A., Martin, M., … Wapnir, I. L. (2014). Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. LANCET ONCOLOGY, 15(2), 156–63.
- Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
  Zhang, H., Cohen, A. L., Krishnakumar, S., Wapnir, I. L., Veeriah, S., Deng, G., … Jeffrey, S. S. (2014). Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition. Breast Cancer Research , 16(2), R36-?
- PREDICT: Instituting an Educational Time Out in the Operating Room.
  Yang, R. L., Esquivel, M., Erdrich, J., Lau, J., Melcher, M. L., & Wapnir, I. L. (2014). PREDICT: Instituting an Educational Time Out in the Operating Room. Journal of Graduate Medical Education, 6(2), 382–83.
- Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition
  Zhang, H., Cohen, A. L., Krishnakumar, S., Wapnir, I. L., Veeriah, S., Deng, G., … Jeffrey, S. S. (2014). Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition. BREAST CANCER RESEARCH, 16(2).
- Indocyanine green and fluorescence lymphangiography for sentinel lymph node identification in cutaneous melanoma.
  Cloyd, J. M., Wapnir, I. L., Read, B. M., Swetter, S., & Greco, R. S. (2014). Indocyanine green and fluorescence lymphangiography for sentinel lymph node identification in cutaneous melanoma. Journal of Surgical Oncology, 110(7), 888–92.
- Indocyanine Green and Fluorescence Lymphangiography for Sentinel Lymph Node Identification in Cutaneous Melanoma
  Cloyd, J. M., Wapnir, I. L., Read, B. M., Swetter, S., & Greco, R. S. (2014). Indocyanine Green and Fluorescence Lymphangiography for Sentinel Lymph Node Identification in Cutaneous Melanoma. JOURNAL OF SURGICAL ONCOLOGY, 110(7), 888–92.
- Impact of histological subtype on long-term outcomes of neuroendocrine carcinoma of the breast
  Cloyd, J. M., Yang, R. L., Allison, K. H., Norton, J. A., Hernandez-Boussard, T., & Wapnir, I. L. (2014). Impact of histological subtype on long-term outcomes of neuroendocrine carcinoma of the breast. BREAST CANCER RESEARCH AND TREATMENT, 148(3), 637–44.
- Initial results with preoperative tattooing of biopsied axillary lymph nodes and correlation to sentinel lymph nodes in breast cancer patients.
  Choy, N., Lipson, J., Porter, C., Ozawa, M., Kieryn, A., Pal, S., … Wapnir, I. (2015). Initial results with preoperative tattooing of biopsied axillary lymph nodes and correlation to sentinel lymph nodes in breast cancer patients. Annals of Surgical Oncology, 22(2), 377–82.
- Maastricht Delphi Consensus on Event Definitions for Classification of Recurrence in Breast Cancer Research
  Moossdorff, M., van Roozendaal, L. M., Strobbe, L. J. A., Aebi, S., Cameron, D. A., Dixon, J. M., … Smidt, M. L. (2014). Maastricht Delphi Consensus on Event Definitions for Classification of Recurrence in Breast Cancer Research. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 106(12).
- Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.
  Telli, M. L., Jensen, K. C., Vinayak, S., Kurian, A. W., Lipson, J. A., Flaherty, P. J., … Ford, J. M. (2015). Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. Journal of Clinical Oncology , 33(17), 1895–1901.
- Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105
  Telli, M. L., Jensen, K. C., Vinayak, S., Kurian, A. W., Lipson, J. A., Flaherty, P. J., … Ford, J. M. (2015). Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. JOURNAL OF CLINICAL ONCOLOGY, 33(17), 1895–U57.
- Impact of histological subtype on long-term outcomes of neuroendocrine carcinoma of the breast.
  Cloyd, J. M., Yang, R. L., Allison, K. H., Norton, J. A., Hernandez-Boussard, T., & Wapnir, I. L. (2014). Impact of histological subtype on long-term outcomes of neuroendocrine carcinoma of the breast. Breast Cancer Research and Treatment, 148(3), 637–44.
- Addressing Inherited Predisposition for Breast Cancer in Transplant Recipients
  Yang, R. L., Kurian, A. W., Winton, L. M., Weill, D., Patel, K., Kingham, K., & Wapnir, I. L. (2016). Addressing Inherited Predisposition for Breast Cancer in Transplant Recipients. JOURNAL OF SURGICAL ONCOLOGY, 113(6), 605–8.
- Using intraoperative laser angiography to safeguard nipple perfusion in nipple-sparing mastectomies.
  Dua, M. M., Bertoni, D. M., Nguyen, D., Meyer, S., Gurtner, G. C., & Wapnir, I. L. (2015). Using intraoperative laser angiography to safeguard nipple perfusion in nipple-sparing mastectomies. Gland Surgery, 4(6), 497–505.
- Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer.
  Tsai, J., Bertoni, D., Hernandez-Boussard, T., Telli, M. L., & Wapnir, I. L. (2016). Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer. Annals of Surgical Oncology, 23(10), 3310–16.
- Protecting Nipple Perfusion by Devascularization and Surgical Delay in Patients at Risk for Ischemic Complications During Nipple-Sparing Mastectomies
  Bertoni, D. M., Dung Nguyen, D., Rochlin, D., Hernandez-Boussard, T., Meyer, S., Choy, N., … Wapnir, I. L. (2016). Protecting Nipple Perfusion by Devascularization and Surgical Delay in Patients at Risk for Ischemic Complications During Nipple-Sparing Mastectomies. ANNALS OF SURGICAL ONCOLOGY, 23(8), 2665–72.
- Rising Bilateral Mastectomy Rates Among Neoadjuvant Chemotherapy Recipients in California From 1998 to 2012.
  Wapnir, I. L., Kurian, A. W., Lichtensztajn, D. Y., Clarke, C. A., & Gomez, S. L. (2016). Rising Bilateral Mastectomy Rates Among Neoadjuvant Chemotherapy Recipients in California From 1998 to 2012. Annals of Surgery, -?
- Regression of experimental NIS-expressing breast cancer brain metastases in response to radioiodide/gemcitabine dual therapy.
  Renier, C., Do, J., Reyna-Neyra, A., Foster, D., De, A., Vogel, H., … Wapnir, I. (2016). Regression of experimental NIS-expressing breast cancer brain metastases in response to radioiodide/gemcitabine dual therapy. Oncotarget.
- Breast Cancer Survivorship: Why, What and When?
  Gass, J., Dupree, B., Pruthi, S., Radford, D., Wapnir, I., Antoszewska, R., … Johnson, N. (2016). Breast Cancer Survivorship: Why, What and When? Annals of Surgical Oncology, 23(10), 3162–67.
- Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ
  Morrow, M., Van Zee, K. J., Solin, L. J., Houssami, N., Chavez-MacGregor, M., Harris, J. R., … Moran, M. S. (2016). Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ. JOURNAL OF CLINICAL ONCOLOGY, 34(33), 4040–U166.
- Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ
  Morrow, M., Van Zee, K. J., Solin, L. J., Houssami, N., Chavez-MacGregor, M., Harris, J. R., … Moran, M. S. (2016). Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ. ANNALS OF SURGICAL ONCOLOGY, 23(12), 3801–10.
- Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma in Situ.
  Morrow, M., Van Zee, K. J., Solin, L. J., Houssami, N., Chavez-MacGregor, M., Harris, J. R., … Moran, M. S. (2016). Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma in Situ. Practical Radiation Oncology, 6(5), 287–95.
- Rising bilateral mastectomy rates among neoadjuvant chemotherapy recipients in California, 1998-2012
  Wapnirr, I., & Kurian, A. (2016). Rising bilateral mastectomy rates among neoadjuvant chemotherapy recipients in California, 1998-2012 . Annals of Surgery.
- Regression of experimental NIS-expressing breast cancer brain metastases in response to radioiodide/gemcitabine dual therapy
  Renier, C., Do, J., Reyna-Neyra, A., Foster, D., De, A., Vogel, H., … Wapnir, I. (2016). Regression of experimental NIS-expressing breast cancer brain metastases in response to radioiodide/gemcitabine dual therapy. ONCOTARGET, 7(34), 54811–24.
- Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ.
  Manders, J. B., Kuerer, H. M., Smith, B. D., McCluskey, C., Farrar, W. B., Frazier, T. G., … White, J. (2016). Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ. Annals of Surgical Oncology, -?
- rising bilateral mastectomy rates among neoadjuvant chemotherapy recipients in California, 1998-2012
  Wapnir, I. (2016). rising bilateral mastectomy rates among neoadjuvant chemotherapy recipients in California, 1998-2012. Annals of Surgery.
- Oncologic Procedures Amenable to Fluorescence-guided Surgery.
  Tipirneni, K. E., Warram, J. M., Moore, L. S., Prince, A. C., de Boer, E., Jani, A. H., … Rosenthal, E. (2016). Oncologic Procedures Amenable to Fluorescence-guided Surgery. Annals of Surgery.
- Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial
  Wapnir, I. L., Gelber, S., Anderson, S. J., Mamounas, E. P., Robidoux, A., Martin, M., … Aebi, S. (2017). Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial. ANNALS OF SURGICAL ONCOLOGY, 24(2), 398–406.
- (527) An internet-based perioperative pain psychology treatment program: results of a randomized controlled trial in breast oncology surgery patients.
  Darnall, B., Wheeler, A., Taub, C., MACKEY, I., Wapnir, I., Schultz, C., … Flood, P. (2016). (527) An internet-based perioperative pain psychology treatment program: results of a randomized controlled trial in breast oncology surgery patients. Journal of Pain , 17(4S), S106-?
- Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ
  Manders, J. B., Kuerer, H. M., Smith, B. D., McCluskey, C., Farrar, W. B., Frazier, T. G., … White, J. (2017). Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ. ANNALS OF SURGICAL ONCOLOGY, 24(3), 660–68.
- Will oncotype DX DCIS testing guide therapy? A single-institution correlation of oncotype DX DCIS results with histopathologic findings and clinical management decisions.
  Lin, C.-Y. Y., Mooney, K., Choy, W., Yang, S.-R. R., Barry-Holson, K., Horst, K., … Allison, K. (2017). Will oncotype DX DCIS testing guide therapy? A single-institution correlation of oncotype DX DCIS results with histopathologic findings and clinical management decisions. Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc.
- Surgical Breast Cancer Care for Hispanic Patients Who Travel to an Academic Cancer Center
  Yang, R., Rhoads, K., & Wapnir, I. (2016). Surgical Breast Cancer Care for Hispanic Patients Who Travel to an Academic Cancer Center. ANNALS OF SURGICAL ONCOLOGY. SPRINGER.
- Bridging gaps in breast cancer care: A pilot forum for mental health professionals
  Yang, R., Rabinowitz, B., Frank, M., Schapira, L., & Wapnir, I. (2018). Bridging gaps in breast cancer care: A pilot forum for mental health professionals. CANCER RESEARCH, 78(4).
- Indocyanine Green and Fluorescence Lymphangiography for Sentinel Lymph Node Identification in Melanoma
  Cloyd, J. M., Wapnir, I. L., Read, B. M., & Greco, R. S. (2014). Indocyanine Green and Fluorescence Lymphangiography for Sentinel Lymph Node Identification in Melanoma. ANNALS OF SURGICAL ONCOLOGY, 21, S121.
- Axillary reverse mapping with indocyanine green or isosulfan blue demonstrate similar crossover rates to radiotracer identified sentinel nodes
  Foster, D., Choy, N., Porter, C., Ahmed, S., & Wapnir, I. (2018). Axillary reverse mapping with indocyanine green or isosulfan blue demonstrate similar crossover rates to radiotracer identified sentinel nodes. JOURNAL OF SURGICAL ONCOLOGY, 117(3), 336–40.
- Initial Results With Black Ink Tattooing of Biopsied Axillary Lymph Nodes
  Choy, N. S., Lipson, J., Kieryn, A., Porter, C., Ikeda, D., Pal, S., … Wapnir, I. (2014). Initial Results With Black Ink Tattooing of Biopsied Axillary Lymph Nodes. ANNALS OF SURGICAL ONCOLOGY. SPRINGER.
- Correlation of percutaneously biopsied axillary lymph nodes marked with black tattoo ink prior to neoadjuvant chemotherapy with sentinel lymph nodes in breast cancer patients
  Choy, N., Lipson, J., Pal, S., Ikeda, D., Trinh, L., Allison, K., … Wapnir, I. (2015). Correlation of percutaneously biopsied axillary lymph nodes marked with black tattoo ink prior to neoadjuvant chemotherapy with sentinel lymph nodes in breast cancer patients. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Descriptive Findings on the Utility of Indocyanine Green and Isosulfan Blue in the Mapping of Arm-Draining Lymphatics and Nodes
  Wapnir, I. L., Ahmed, S. M., Choy, N. S., Porter, C., & Meyer, S. (2014). Descriptive Findings on the Utility of Indocyanine Green and Isosulfan Blue in the Mapping of Arm-Draining Lymphatics and Nodes. ANNALS OF SURGICAL ONCOLOGY. SPRINGER.
- The Role of Tattooing Biopsied Axillary Lymph Nodes in Patients Undergoing Neoadjuvant Therapy
  Patel, R., Choy, N., Tsai, J., Pal, S., Lipson, J., & Wapnir, I. (2018). The Role of Tattooing Biopsied Axillary Lymph Nodes in Patients Undergoing Neoadjuvant Therapy. ANNALS OF SURGICAL ONCOLOGY, 25, S94.
- Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial
  Wapnir, I. L., Price, K. N., Anderson, S. J., Robidoux, A., Martin, M., Nortier, J. W. R., … Aebi, S. (2018). Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. JOURNAL OF CLINICAL ONCOLOGY, 36(11), 1073-+.
- Intraoperative Tumor Detection Using a Ratiometric Activatable Fluorescent Peptide: A First-in-Human Phase 1 Study (vol 24, pg 3167, 2017)
  Unkart, J. T., Chen, S. L., Wapnir, I. L., Gonzalez, J. E., Harootunian, A., & Wallace, A. M. (2017). Intraoperative Tumor Detection Using a Ratiometric Activatable Fluorescent Peptide: A First-in-Human Phase 1 Study (vol 24, pg 3167, 2017). ANNALS OF SURGICAL ONCOLOGY, 24, S693.
- Pathological confirmation of pre-chemotherapy biopsied and tattooed axillary lymph nodes
  Patel, R., MacKerricher, W., Tsai, J., Wood, L., Allison, K., & Wapnir, I. (2018). Pathological confirmation of pre-chemotherapy biopsied and tattooed axillary lymph nodes. ANNALS OF SURGICAL ONCOLOGY, 25, 426–27.
- Nipple Perfusion Is Preserved by Staged Devascularization in High-Risk Nipple-Sparing Mastectomies
  Bertoni, D. M., Nguyen, D., Rochlin, D., Choy, N., Gurtner, G., & Wapnir, I. (2015). Nipple Perfusion Is Preserved by Staged Devascularization in High-Risk Nipple-Sparing Mastectomies. ANNALS OF SURGICAL ONCOLOGY. SPRINGER.
- Dose-Escalated, Intratumoral TLR9 Agonist and Low-Dose Radiation Induce Abscopal Effects in Follicular Lymphoma
  Kohrt, H. E., Chu, J., Brody, J., Czerwinski, D. K., Chester, C., Sadaram, M., … Levy, R. (2014). Dose-Escalated, Intratumoral TLR9 Agonist and Low-Dose Radiation Induce Abscopal Effects in Follicular Lymphoma. BLOOD, 124(21).
- The Diagnostic Reliability of Nipple Discharge Cytology
  Kalu, O., Chow, C., Wheeler, A., Kong, C., & Wapnir, I. (2010). The Diagnostic Reliability of Nipple Discharge Cytology. ANNALS OF SURGICAL ONCOLOGY, 17(2), S176.
- Hispanic Breast Cancer Patients Travel Further for Equitable Surgical Care at a Comprehensive Cancer Center.
  Yang, R. L., & Wapnir, I. (2018). Hispanic Breast Cancer Patients Travel Further for Equitable Surgical Care at a Comprehensive Cancer Center. Health Equity, 2(1), 109–16.
- Chemotherapy (CT) for isolated locoregional recurrence (ILRR) of breast cancer in ER-positive (ER plus ) and ER-negative (ER-) cohorts: Final analysis of the CALOR trial
  Wapnir, I., Price, K. N., Anderson, S. J., Robidoux, A., Nortier, M. M. J. W. R., Paterson, A. H. G., … Aebi, S. P. (2017). Chemotherapy (CT) for isolated locoregional recurrence (ILRR) of breast cancer in ER-positive (ER plus ) and ER-negative (ER-) cohorts: Final analysis of the CALOR trial. JOURNAL OF CLINICAL ONCOLOGY, 35.
- Matching for Fellowship Interviews
  Melcher, M. L., Ashlagi, I., & Wapnir, I. (2018). Matching for Fellowship Interviews. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 320(16), 1639–40.
- Use of Preoperative Radiation Therapy in Early and Advanced Stage Breast Cancer
  Koenig, J. L., Kozak, M., Sabolch, A., Wapnir, I. L., Horst, K. C., Tsai, C. J., & Pollom, E. (2018). Use of Preoperative Radiation Therapy in Early and Advanced Stage Breast Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 102(3), E589.
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
  von Minckwitz, G., Huang, C.-S., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., … Geyer, C. E. (2018). Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. The New England Journal of Medicine.
- Current Strategies for the Management of Locoregional Breast Cancer Recurrence
  Wapnir, I. L., & Khan, A. (2019). Current Strategies for the Management of Locoregional Breast Cancer Recurrence. ONCOLOGY-NEW YORK, 33(1), 19–25.
- Circulating tumor DNA and burden of disease in breast cancer
  Hoffman, A., Aleshin, A., Banks, K., Talasaz, A. A., Eltoukhy, H., Telli, M., & Wapnir, I. (2017). Circulating tumor DNA and burden of disease in breast cancer. ANNALS OF SURGICAL ONCOLOGY, 24, 304–5.
- Reducing the Burden of Fellowship Interviews-Reply.
  Melcher, M. L., Ashlagi, I., & Wapnir, I. (2019). Reducing the Burden of Fellowship Interviews-Reply. JAMA, 321(11), 1107.
- Molecular receptor profiles in male mutation carriers with breast cancer
  Wapnir, I., Kingham, K., Mills, M., Ford, J., & Kurian, A. (2017). Molecular receptor profiles in male mutation carriers with breast cancer. ANNALS OF SURGICAL ONCOLOGY, 24, 112–13.
- PrECOG 0105: Final efficacy results from a phase II study of gemcitabine (G) and carboplatin (C) plus iniparib (BSI-201) as neoadjuvant therapy for triple-negative (TN) and BRCA1/2 mutation-associated breast cancer
  Telli, M. L., Jensen, K. C., Kurian, A. W., Vinayak, S., Lipson, J. A., Schackmann, E. A., … Ford, J. M. (2013). PrECOG 0105: Final efficacy results from a phase II study of gemcitabine (G) and carboplatin (C) plus iniparib (BSI-201) as neoadjuvant therapy for triple-negative (TN) and BRCA1/2 mutation-associated breast cancer. JOURNAL OF CLINICAL ONCOLOGY, 31(15).
- A technique for preoperative axillary lymph node tattooing in patients with breast cancer
  Wapnir, I. L., Downey, J. R., Lipson, J. A., & Ikeda, D. M. (2016). A technique for preoperative axillary lymph node tattooing in patients with breast cancer. CANCER RESEARCH, 76.
- Comparative analysis of time delays to initiation of chemotherapy in women undergoing oocyte retrieval with cryopreservation
  De la Pena, J. L., Madrigrano, A., Westphal, L., & Wapnir, I. L. (2008). Comparative analysis of time delays to initiation of chemotherapy in women undergoing oocyte retrieval with cryopreservation. ANNALS OF SURGICAL ONCOLOGY, 15, 81.
- Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a prospective randomized trial evaluating chemotherapy after local therapy for isolated locoregional recurrences
  Wapnir, I. L., Zahrieh, D., & Aebi, S. (2008). Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a prospective randomized trial evaluating chemotherapy after local therapy for isolated locoregional recurrences. ANNALS OF SURGICAL ONCOLOGY, 15, 9.
- Survival after IBTR in NSABP node negative protocols B-13, B-14, B-19, B-20 and B-23.
  Wapnir, Anderson, S., Mamounas, E., Geyer, C., Hyeon-Jeong, J., Costantino, J., … Wolmark, N. (2005). Survival after IBTR in NSABP node negative protocols B-13, B-14, B-19, B-20 and B-23. JOURNAL OF CLINICAL ONCOLOGY, 23(16), 8S.
- Intraoperative Tumor Detection Using a Ratiometric Activatable Fluorescent Peptide: A First-in-Human Phase 1 Study
  Unkart, J. T., Chen, S. L., Wapnir, I. L., Gonzalez, J. E., Harootunian, A., & Wallace, A. M. (2017). Intraoperative Tumor Detection Using a Ratiometric Activatable Fluorescent Peptide: A First-in-Human Phase 1 Study. ANNALS OF SURGICAL ONCOLOGY, 24(11), 3167–73.
- Disease-Free Survival Using Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy
  Tsai, J., Bertoni, D., Tsai, C. Y., Hernandez-Boussard, T., & Wapnir, I. (2016). Disease-Free Survival Using Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy. ANNALS OF SURGICAL ONCOLOGY, 23, 162–63.
- Lymph node ratio as prognostic after neoadjuvant therapy in breast cancer.
  Bertoni, D. M., Hernandez-Boussard, T., & Wapnir, I. (2015). Lymph node ratio as prognostic after neoadjuvant therapy in breast cancer. JOURNAL OF CLINICAL ONCOLOGY, 33(28).
- The 12-gene DCIS score assay: Impact on radiation treatment (XRT) recommendations and clinical utility
  Manders, J. B., Kuerer, H. M., Smith, B. D., McCluskey, C., Farrar, W. B., Frazier, T. G., … White, J. (2016). The 12-gene DCIS score assay: Impact on radiation treatment (XRT) recommendations and clinical utility. CANCER RESEARCH, 76.
- A Phase II Study of Gemcitabine and Carboplatin (GC) Plus Iniparib (BSI-201) as Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer.
  Telli, M. L., Kurian, A. W., Jensen, K. C., Vinayak, S., Flaherty, P., Lipson, J. A., … Ford, J. M. (2011). A Phase II Study of Gemcitabine and Carboplatin (GC) Plus Iniparib (BSI-201) as Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer. CANCER RESEARCH, 71.
- High Percentage of Triple Negative Tumors Present as Palpable Masses
  Kalu, O. N., Kurian, A., & Wapnir, I. (2010). High Percentage of Triple Negative Tumors Present as Palpable Masses. CANCER RESEARCH, 70.
- Maastricht Delphi Consensus on Event Definitions for Classification of Recurrence in Breast Cancer Research
  Moossdorff, M., Van Roozendaal, L. M., Strobbe, L. J., Aebi, S., Cameron, D. A., Dixon, M., … Smidt, M. L. (2015). Maastricht Delphi Consensus on Event Definitions for Classification of Recurrence in Breast Cancer Research. ANNALS OF SURGICAL ONCOLOGY, 22, S132.
- Is Lymph Node Ratio Prognostic after Neoadjuvant Therapy for Breast Cancer?
  Bertoni, D. M., Hernandez-Boussard, T., & Wapnir, I. L. (2015). Is Lymph Node Ratio Prognostic after Neoadjuvant Therapy for Breast Cancer? ANNALS OF SURGICAL ONCOLOGY, 22, S52.
- FIVE YEAR SAFETY AND FERTILITY OUTCOMES IN WOMEN WHO UNDERWENT OVARIAN STIMULATION FOR FERTILITY PRESERVATION PRIOR TO CHEMOTHERAPY FOR INVASIVE BREAST CANCER.
  Kort, J. D., Wapnir, I., Seiger, K., & Westphal, L. (2013). FIVE YEAR SAFETY AND FERTILITY OUTCOMES IN WOMEN WHO UNDERWENT OVARIAN STIMULATION FOR FERTILITY PRESERVATION PRIOR TO CHEMOTHERAPY FOR INVASIVE BREAST CANCER. FERTILITY AND STERILITY, 100(3), S116–S117.
- Increasing Use of Lumpectomy in Men with Breast Cancer: Outcomes Analysis of SEER Data 1983-2009
  Cloyd, J. M., & Wapnir, I. L. (2013). Increasing Use of Lumpectomy in Men with Breast Cancer: Outcomes Analysis of SEER Data 1983-2009. ANNALS OF SURGICAL ONCOLOGY, 20, S50.
- Evaluation of the Oncotype Dx recurrence score (RS) in hormone-positive ipsilateral breast tumor recurrences
  Wapnir, I., & Florero, M. (2012). Evaluation of the Oncotype Dx recurrence score (RS) in hormone-positive ipsilateral breast tumor recurrences. JOURNAL OF CLINICAL ONCOLOGY, 30(15).
- Long-term outcomes after invasive breast tumor recurrence (IBTR) in women with DCIS in NSABP B-17 and B-24
  Wapnir, I., Dignam, J., Julian, T. B., Land, S., Mamounas, E. P., Anderson, S., … Wolmark, N. (2007). Long-term outcomes after invasive breast tumor recurrence (IBTR) in women with DCIS in NSABP B-17 and B-24. JOURNAL OF CLINICAL ONCOLOGY, 25(18).
- May the Interview Be With You: Signal Your Preferences.
  Melcher, M. L., Wapnir, I., & Ashlagi, I. (2019). May the Interview Be With You: Signal Your Preferences. Journal of Graduate Medical Education, 11(1), 39–40.
- Matching for Fellowship Interviews.
  Melcher, M. L., Ashlagi, I., & Wapnir, I. (2018). Matching for Fellowship Interviews. JAMA, 320(16), 1639–1640.
- Erratum to: Intraoperative Tumor Detection Using a Ratiometric Activatable Fluorescent Peptide: A First-in-Human Phase 1 Study.
  Unkart, J. T., Chen, S. L., Wapnir, I. L., González, J. E., Harootunian, A., & Wallace, A. M. (2017). Erratum to: Intraoperative Tumor Detection Using a Ratiometric Activatable Fluorescent Peptide: A First-in-Human Phase 1 Study. Annals of Surgical Oncology, 24(Suppl 3), 693.
- Reducing the Burden of Fellowship Interviews Reply
  Melcher, M. L., Ashlagi, I., & Wapnir, I. (2019). Reducing the Burden of Fellowship Interviews Reply. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 321(11), 1107.
- Pretreatment Tattoo Marking of Suspicious Axillary Lymph Nodes: Reliability and Correlation with Sentinel Lymph Node.
  Patel, R., MacKerricher, W., Tsai, J., Choy, N., Lipson, J., Ikeda, D., … Wapnir, I. L. (2019). Pretreatment Tattoo Marking of Suspicious Axillary Lymph Nodes: Reliability and Correlation with Sentinel Lymph Node. Annals of Surgical Oncology.
- Clinical and pathological features of breast cancer among men and women with ATM and CDH1 mutations
  Tsang, A., Kingham, K., Kurian, A., Ford, J., & Wapnir, I. (2019). Clinical and pathological features of breast cancer among men and women with ATM and CDH1 mutations. ANNALS OF SURGICAL ONCOLOGY. SPRINGER.
- Benefits of an interview match for breast fellowship positions
  Wapnir, I., Lo, I., Roth, A., Ashlagi, I., & Melcher, M. (2019). Benefits of an interview match for breast fellowship positions. ANNALS OF SURGICAL ONCOLOGY, 26, 279–80.
- Preliminary results of a multi-center feasibility trial for real-time, intraoperative detection of residual breast cancer in lumpectomy cavity margins using the LUM Imaging System
  Smith, B., Kelly, B., Hunt, K., Hwang, S., Wapnir, I., Gadd, M., … Kacena, K. (2019). Preliminary results of a multi-center feasibility trial for real-time, intraoperative detection of residual breast cancer in lumpectomy cavity margins using the LUM Imaging System. ANNALS OF SURGICAL ONCOLOGY. SPRINGER.
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
  von Minckwitz, G., Huang, C.-S., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., … Geyer, C. E. (2019). Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. NEW ENGLAND JOURNAL OF MEDICINE, 380(7), 617–28.
- Expansion into multiple institutions for training in the use of the LUM Imaging System for intraoperative detection of residual cancer in the tumor bed of female subjects with breast cancer
  Ferrer, J. M., Hwang, S., Hunt, K., Dodge, D., Chagpar, A., Grobmyer, S., … Smith, B. (2018). Expansion into multiple institutions for training in the use of the LUM Imaging System for intraoperative detection of residual cancer in the tumor bed of female subjects with breast cancer. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Methotrexate in the Treatment of Idiopathic Granulomatous Mastitis.
  Postolova, A., Troxell, M. L., Wapnir, I. L., & Genovese, M. C. (2019). Methotrexate in the Treatment of Idiopathic Granulomatous Mastitis. The Journal of Rheumatology.
- Intratumoral plasmid IL-12 and electroporation in pre-treated inoperable locally advanced or recurrent triple-negative breast cancer (TNBC)
  Telli, M. L., Zablotsky, K., Gargosky, S. E., Twitty, C. G., & Wapnir, I. L. (2018). Intratumoral plasmid IL-12 and electroporation in pre-treated inoperable locally advanced or recurrent triple-negative breast cancer (TNBC). CANCER RESEARCH, 78(13).
- KATHERINE: Trastuzumab emtansine vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer
  Mamounas, E. P., Geyer, C. E., Huang, C.-S., Mano, M. S., Loibl, S., Untch, M., … von Minckwitz, G. (2019). KATHERINE: Trastuzumab emtansine vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer. SWISS MEDICAL WEEKLY, 149, 13S.
- Pretreatment Tattoo Marking of Suspicious Axillary Lymph Nodes: Reliability and Correlation with Sentinel Lymph Node
  Patel, R., MacKerricher, W., Tsai, J., Choy, N., Lipson, J., Ikeda, D., … Wapnir, I. L. (2019). Pretreatment Tattoo Marking of Suspicious Axillary Lymph Nodes: Reliability and Correlation with Sentinel Lymph Node. ANNALS OF SURGICAL ONCOLOGY, 26(8), 2452–58.
- Mucocele-Like Lesions of the Breast on Core Needle Biopsy: an Institutional review and Meta-Analysis of the Literature
  Ylagan, L., Allison, K., Ikeda, D., & Wapnir, I. (2019). Mucocele-Like Lesions of the Breast on Core Needle Biopsy: an Institutional review and Meta-Analysis of the Literature. MODERN PATHOLOGY. NATURE PUBLISHING GROUP.
- Mucocele-Like Lesions of the Breast on Core Needle Biopsy: an Institutional review and Meta-Analysis of the Literature
  Ylagan, L., Allison, K., Ikeda, D., & Wapnir, I. (2019). Mucocele-Like Lesions of the Breast on Core Needle Biopsy: an Institutional review and Meta-Analysis of the Literature. LABORATORY INVESTIGATION. NATURE PUBLISHING GROUP.
- Intratumoral tavokinogene telseplasmid and electroporation in pre-treated inoperable locally advanced or recurrent triple-negative breast cancer
  Telli, M. L., Zablotsky, K., Le, M. H., Canton, D., Browning, E., Bannavong, D., … Wapnir, I. (2019). Intratumoral tavokinogene telseplasmid and electroporation in pre-treated inoperable locally advanced or recurrent triple-negative breast cancer. CANCER RESEARCH, 79(4).
- A phase 2 study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation with pembrolizumab in patients with inoperable locally advanced or metastatic triple negative breast cancer
  Telli, M. L., Wapnir, I., Vinayak, S., Chang, J., Alemany, C., Twitty, C., & Gargosky, S. (2019). A phase 2 study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation with pembrolizumab in patients with inoperable locally advanced or metastatic triple negative breast cancer. CANCER RESEARCH, 79(4).
- Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE
  Geyer, C. E., Huang, C.-S., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., … von Minckwitz, G. (2019). Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE. CANCER RESEARCH, 79(4).
- Relationship between rising bilateral mastectomy rates and increased use of neoadjuvant chemotherapy (NAC) in California, 1998-2012.
  Wapnir, I., Kurian, A. W., Lichtensztajn, D., Clarke, C. A., & Gomez, S. L. (2016). Relationship between rising bilateral mastectomy rates and increased use of neoadjuvant chemotherapy (NAC) in California, 1998-2012. JOURNAL OF CLINICAL ONCOLOGY, 34(15).
- Use of Preoperative Radiation Therapy in Early-stage and Locally Advanced Breast Cancer
  Koenig, J. L., Kozak, M. M., Sabolch, A., Horst, K., Tsai, J., Wapnir, I. L., & Pollom, E. (2019). Use of Preoperative Radiation Therapy in Early-stage and Locally Advanced Breast Cancer. CUREUS, 11(9).
- Expansion into multiple institutions for training in the use of the LUM Imaging System for intraoperative detection of residual cancer in the tumor bed of female subjects with breast cancer
  Smith, K., Ferrer, J. M., Smith, B. L., Hwang, E. S., Hunt, K. K., Dodge, D. G., … Geissler, F. (2019). Expansion into multiple institutions for training in the use of the LUM Imaging System for intraoperative detection of residual cancer in the tumor bed of female subjects with breast cancer. CANCER RESEARCH, 79(13).
- Use of Preoperative Radiation Therapy in Early-stage and Locally Advanced Breast Cancer.
  Koenig, J. L., Kozak, M. M., Sabolch, A., Horst, K., Tsai, J., Wapnir, I. L., & Pollom, E. (2019). Use of Preoperative Radiation Therapy in Early-stage and Locally Advanced Breast Cancer. Cureus, 11(9), e5748.
- Dilemma in management of hemorrhagic myositis in dermatomyositis.
  Chandler, J. M., Kim, Y. J., Bauer, J. L., & Wapnir, I. L. (2019). Dilemma in management of hemorrhagic myositis in dermatomyositis. Rheumatology International.
- Will oncotype DX DCIS testing guide therapy? A single-institution correlation of oncotype DX DCIS results with histopathologic findings and clinical management decisions
  Lin, C.-Y., Mooney, K., Choy, W., Yang, S.-R., Barry-Holson, K., Horst, K., … Allison, K. (2018). Will oncotype DX DCIS testing guide therapy? A single-institution correlation of oncotype DX DCIS results with histopathologic findings and clinical management decisions. MODERN PATHOLOGY, 31(4), 562–68.
- The Impact of Device Innovation on Clinical Outcomes in Expander-based Breast Reconstruction
  Momeni, A., Li, A. Y., Tsai, J., Wan, D., Karin, M. R., & Wapnir, I. L. (2019). The Impact of Device Innovation on Clinical Outcomes in Expander-based Breast Reconstruction. PLASTIC AND RECONSTRUCTIVE SURGERY-GLOBAL OPEN, 7(12).
- A randomized phase II study comparing surgical excision versus NeOadjuvant Radiotherapy followed by delayed surgical excision of Ductal carcinoma In Situ (NORDIS)
  Wapnir, I., DeMartini, W., Allison, K., Stone, K., Dirbas, F., Marquez, C., … Horst, K. (2020). A randomized phase II study comparing surgical excision versus NeOadjuvant Radiotherapy followed by delayed surgical excision of Ductal carcinoma In Situ (NORDIS). CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysis
  Mano, M. S., Loibl, S., Mamounas, E. P., von Minckwitz, G., Huang, C.-S., Untch, M., … Geyer, C. E. (2020). Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysis. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Expansion into multiple institutions for training in the use of the LUM Imaging System for intraoperative detection of residual cancer in the tumor bed of female subjects with breast cancer
  Smith, K., Ferrer, J., Carr, D., Blumencranz, P., Dodge, D., Dekhne, N., … Smith, B. (2020). Expansion into multiple institutions for training in the use of the LUM Imaging System for intraoperative detection of residual cancer in the tumor bed of female subjects with breast cancer. CANCER RESEARCH, 80(4).
- Results from the expansion into multiple institutions for training in the use of the LUM imaging system for intraoperative detection of residual cancer in the tumor bed of female subjects with breast cancer clinical trial
  Ferrer, J., Carr, D., Blumencranz, P., Dodge, D., Dekhne, N., Wapnir, I., … Smith, B. (2020). Results from the expansion into multiple institutions for training in the use of the LUM imaging system for intraoperative detection of residual cancer in the tumor bed of female subjects with breast cancer clinical trial. CANCER RESEARCH, 80(4).
- Phase 2, open-label study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation in combination with intravenous pembrolizumab therapy in patients with inoperable locally advanced or metastatic triple-negative breast cancer (mTNBC) (KEYNOTE-890/OMS-I141)
  Telli, M. L., Wapnir, I., Devitt, B., Cuff, K., Soliman, H., Vinayak, S., … Joshi, R. (2020). Phase 2, open-label study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation in combination with intravenous pembrolizumab therapy in patients with inoperable locally advanced or metastatic triple-negative breast cancer (mTNBC) (KEYNOTE-890/OMS-I141). CANCER RESEARCH, 80(4).
- Primary analysis of NRG-BR005, a phase II trial assessing accuracy of tumor bed biopsies in predicting pathologic complete response (pCR) in patients with clinical/radiological complete response after neoadjuvant chemotherapy (NCT) to explore the feasibility of breast-conserving treatment without surgery
  Basik, M., Cecchini, R. S., De Los Santos, J. F., Umphrey, H. R., Julian, T. B., Mamounas, E. P., … Wolmark, N. (2020). Primary analysis of NRG-BR005, a phase II trial assessing accuracy of tumor bed biopsies in predicting pathologic complete response (pCR) in patients with clinical/radiological complete response after neoadjuvant chemotherapy (NCT) to explore the feasibility of breast-conserving treatment without surgery. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Immediate Targeted Nipple-Areolar Complex Reinnervation: Improving Outcomes in Gender-affirming Mastectomy.
  Rochlin, D. H., Brazio, P., Wapnir, I., & Nguyen, D. (2020). Immediate Targeted Nipple-Areolar Complex Reinnervation: Improving Outcomes in Gender-affirming Mastectomy. Plastic and Reconstructive Surgery. Global Open, 8(3), e2719.
- The Impact of Device Innovation on Clinical Outcomes in Expander-based Breast Reconstruction.
  Momeni, A., Li, A. Y., Tsai, J., Wan, D., Karin, M. R., & Wapnir, I. L. (2019). The Impact of Device Innovation on Clinical Outcomes in Expander-based Breast Reconstruction. Plastic and Reconstructive Surgery. Global Open, 7(12), e2524.
- Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.
  Frank, M. J., Khodadoust, M. S., Czerwinski, D. K., Haabeth, O. A., Chu, M. P., Miklos, D. B., … Levy, R. (2020). Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. The Journal of Experimental Medicine, 217(9).
- Immediate Targeted Nipple-Areolar Complex Re-Innervation: Improving Outcomes in Immediate Autologous Breast Reconstruction
  Tevlin, R., Wapnir, I. L., & Nguyen, D. (2020). Immediate Targeted Nipple-Areolar Complex Re-Innervation: Improving Outcomes in Immediate Autologous Breast Reconstruction. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 231(4), S226–S227.
- Staged Approach to Autologous Reconstruction in the Ptotic Breast: A Comparative Study.
  Deptula, P., Yesantharao, P., Wapnir, I., & Nguyen, D. (2021). Staged Approach to Autologous Reconstruction in the Ptotic Breast: A Comparative Study. Annals of Plastic Surgery.
- Intratumoral plasmid IL-12 expands CD8+ T cells and induces a CXCR3 gene signature in triple-negative breast tumors that sensitizes patients to anti-PD-1 therapy.
  Telli, M. L., Nagata, H., Wapnir, I. L., Acharya, C., Zablotsky, K. E., Fox, B. A., … Crosby, E. J. (2021). Intratumoral plasmid IL-12 expands CD8+ T cells and induces a CXCR3 gene signature in triple-negative breast tumors that sensitizes patients to anti-PD-1 therapy. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
- INTRATUMORAL PLASMID IL-12 EXPANDS CD8+T CELLS AND INDUCES A CLINICALLY VALIDATED CXCR3 SIGNATURE IN TRIPLE-NEGATIVE BREAST CANCER
  Crosby, E., Nagata, H., Telli, M., Acharya, C., Wapnir, I., Zablotsky, K., … Lyerly, H. (2020). INTRATUMORAL PLASMID IL-12 EXPANDS CD8+T CELLS AND INDUCES A CLINICALLY VALIDATED CXCR3 SIGNATURE IN TRIPLE-NEGATIVE BREAST CANCER. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 8, A472.
- Feasibility of Lumpectomy Surgery for Large Ductal Carcinoma In Situ
  Edquilang, J., Tsai, J., Park, Y., & Wapnir, I. (2020). Feasibility of Lumpectomy Surgery for Large Ductal Carcinoma In Situ. ANNALS OF SURGICAL ONCOLOGY, 27(SUPPL 2), S333.
- Intratumoral delivery of tavokinogene telseplasmid (plasmid IL-12) and electroporation induces an immune signature that predicts successful combination in patients
  Crosby, E. J., Nagata, H., Telli, M. L., Acharya, C. R., Wapnir, I., Zablotsky, K., … Lyerly, H. K. (2021). Intratumoral delivery of tavokinogene telseplasmid (plasmid IL-12) and electroporation induces an immune signature that predicts successful combination in patients. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Locally advanced breast cancer
  Aebi, S., & Wapnir, I. (2021). Locally advanced breast cancer. BREAST. CHURCHILL LIVINGSTONE.
- Adjuvant T-DM1 versus Trastuzumab in Patients with Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer: Subgroup Analyses from KATHERINE.
  Mamounas, E. P., Untch, M., Mano, M. S., Huang, C.-S., Geyer, C. E., von Minckwitz, G., … Loibl, S. (2021). Adjuvant T-DM1 versus Trastuzumab in Patients with Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer: Subgroup Analyses from KATHERINE. Annals of Oncology : Official Journal of the European Society for Medical Oncology.
- Two-Stage Versus One-Stage Nipple-Sparing Mastectomy: Timing of Surgery Prevents Nipple Loss
  Ju, T., Momeni, A., Gurtner, G., Nguyen, D., & Wapnir, I. (2021). Two-Stage Versus One-Stage Nipple-Sparing Mastectomy: Timing of Surgery Prevents Nipple Loss. ANNALS OF SURGICAL ONCOLOGY. SPRINGER.
- Skin angiography assisted mastectomy in secondary breast angiosarcoma: Complete clinical response after neoadjuvant immunotherapy.
  Ju, T., Foster, D., Titan, A., Najjar, S., Bean, G. R., Ganjoo, K., & Wapnir, I. (2021). Skin angiography assisted mastectomy in secondary breast angiosarcoma: Complete clinical response after neoadjuvant immunotherapy. The Breast Journal.
- Two-Versus One-Stage Nipple-Sparing Mastectomy: Timing of Surgery Prevents Nipple Loss.
  Ju, T., Chandler, J., Momeni, A., Gurtner, G., Tsai, J., Nguyen, D., & Wapnir, I. (2021). Two-Versus One-Stage Nipple-Sparing Mastectomy: Timing of Surgery Prevents Nipple Loss. Annals of Surgical Oncology.
- Correction to: Two-Stage Versus One-Stage Nipple-Sparing Mastectomy: Timing of Surgery Prevents Nipple Loss.
  Ju, T., Chandler, J., Momeni, A., Gurtner, G., Tsai, J., Nguyen, D., & Wapnir, I. (2021). Correction to: Two-Stage Versus One-Stage Nipple-Sparing Mastectomy: Timing of Surgery Prevents Nipple Loss. Annals of Surgical Oncology.
- ASO Author Reflections: Preventing Nipple Loss by Surgical Delay in Nipple-Sparing Mastectomy.
  Ju, T., Momeni, A., & Wapnir, I. (2021). ASO Author Reflections: Preventing Nipple Loss by Surgical Delay in Nipple-Sparing Mastectomy. Annals of Surgical Oncology.
- Maintaining Contour with a Three-dimensional Interstitial Tissue Marker in 134 Lumpectomies
  Tsang, A. T., Cai, L., Edquilang, J., & Wapnir, I. L. (2021). Maintaining Contour with a Three-dimensional Interstitial Tissue Marker in 134 Lumpectomies. PLASTIC AND RECONSTRUCTIVE SURGERY-GLOBAL OPEN, 9(7).
- Maintaining Contour with a Three-dimensional Interstitial Tissue Marker in 134 Lumpectomies.
  Tsang, A. T., Cai, L., Edquilang, J., & Wapnir, I. L. (2021). Maintaining Contour with a Three-dimensional Interstitial Tissue Marker in 134 Lumpectomies. Plastic and Reconstructive Surgery. Global Open, 9(7), e3696.
- ASO Visual Abstract: Two-Stage Versus One-Stage Nipple-Sparing Mastectomy: Timing of Surgery Prevents Nipple Loss.
  Ju, T., Chandler, J., Momeni, A., Gurtner, G., Tsai, J., Nguyen, D., & Wapnir, I. (2021). ASO Visual Abstract: Two-Stage Versus One-Stage Nipple-Sparing Mastectomy: Timing of Surgery Prevents Nipple Loss. Annals of Surgical Oncology.
- Pivotal Study of the LUM Imaging System for assisting intraoperative detection of residual cancer in the tumor bed of female patients with breast cancer.
  Ferrer, J., Carr, D., Blumencranz, P., Wapnir, I., Dyess, D., Hwang, S., … Smith, B. (2021). Pivotal Study of the LUM Imaging System for assisting intraoperative detection of residual cancer in the tumor bed of female patients with breast cancer. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Surgical Excision Versus Neoadjuvant Radiotherapy Followed by Delayed Surgical Excision of Ductal Carcinoma In Situ (NORDIS).
  Rossi, A. J., Verbus, E. A., Horst, K., De Martini, W., Allison, K., Hernandez, J. M., & Wapnir, I. L. (2021). Surgical Excision Versus Neoadjuvant Radiotherapy Followed by Delayed Surgical Excision of Ductal Carcinoma In Situ (NORDIS). Annals of Surgical Oncology.
- Influence of Imaging Features and Technique on US-guided Tattoo Ink Marking of Axillary Lymph Nodes Removed at Sentinel Lymph Node Biopsy in Women With Breast Cancer
  Pajcini, M., Wapnir, I., Tsai, J., Edquilang, J., DeMartini, W., & Ikeda, D. (2021). Influence of Imaging Features and Technique on US-guided Tattoo Ink Marking of Axillary Lymph Nodes Removed at Sentinel Lymph Node Biopsy in Women With Breast Cancer. JOURNAL OF BREAST IMAGING, 3(5), 583–590.
- Cancer-Associated Fibroblasts Share Highly Conserved Phenotypes and Functions Across Tumor Types and Species
  Foster, D. S., Januszyk, M., Yost, K. E., Chinta, M., Titan, A. L., Wapnir, I. L., … Longaker, M. T. (2021). Cancer-Associated Fibroblasts Share Highly Conserved Phenotypes and Functions Across Tumor Types and Species. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS. ELSEVIER SCIENCE INC.
- Novel Technique of Breast Reconstruction with Omental Fat-Augmented Free Flap Improves Donor Site Morbidity and Reduces Postoperative Narcotic Use
  Deptula, P. L., Zak, Y., Dua, M. M., Wapnir, I. L., & Nguyen, D. (2021). Novel Technique of Breast Reconstruction with Omental Fat-Augmented Free Flap Improves Donor Site Morbidity and Reduces Postoperative Narcotic Use. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS. ELSEVIER SCIENCE INC.
- 10.4300/JGME-D-20-01422.1
  Wapnir, I., Ashlagi, I., Roth, A. E., & Melcher, M. (2021). 10.4300/JGME-D-20-01422.1. Explaining a Potential Interview Match for Graduate Medical Education, 13(6).
- Locally advanced breast cancer.
  Aebi, S., Karlsson, P., & Wapnir, I. L. (2021). Locally advanced breast cancer. Breast (Edinburgh, Scotland).
- Lymphatic Microsurgical Preventive Healing Approach (LYMPHA) for Lymphedema Prevention after Axillary Lymph Node Dissection-A Single Institution Experience and Feasibility of Technique.
  Lipman, K., Luan, A., Stone, K., Wapnir, I., Karin, M., & Nguyen, D. (2021). Lymphatic Microsurgical Preventive Healing Approach (LYMPHA) for Lymphedema Prevention after Axillary Lymph Node Dissection-A Single Institution Experience and Feasibility of Technique. Journal of Clinical Medicine, 11(1).
- Explaining a Potential Interview Match for Graduate Medical Education.
  Wapnir, I., Ashlagi, I., Roth, A. E., Skancke, E., Vohra, A., Lo, I., & Melcher, M. L. (1800). Explaining a Potential Interview Match for Graduate Medical Education. Journal of Graduate Medical Education, 13(6), 764–767.
- Impact of Incision Placement on Ischemic Complications in Microsurgical Breast Reconstruction.
  Tevlin, R., Griffin, M., Karin, M., Wapnir, I., & Momeni, A. (1800). Impact of Incision Placement on Ischemic Complications in Microsurgical Breast Reconstruction. Plastic and Reconstructive Surgery, 149(2), 316–322.
- Creating a Biological Breast Implant with an Omental Fat-Augmented Free Flap.
  Nguyen, D. H., Ma, I. T., Choi, Y. K., Zak, Y., Dua, M. M., & Wapnir, I. L. (1800). Creating a Biological Breast Implant with an Omental Fat-Augmented Free Flap. Plastic and Reconstructive Surgery.
- Minimizing Postoperative Pain in Autologous Breast Reconstruction With the Omental Fat-Augmented Free Flap.
  Deptula, P., Zak, Y., Dua, M., Wapnir, I., & Nguyen, D. (2022). Minimizing Postoperative Pain in Autologous Breast Reconstruction With the Omental Fat-Augmented Free Flap. Annals of Plastic Surgery.
- Two-stage nipple-sparing mastectomy does not compromise oncologic safety
  Thompson, C., Chandler, J., Ju, T., Wapnir, I., & Tsai, J. (2022). Two-stage nipple-sparing mastectomy does not compromise oncologic safety. ANNALS OF SURGICAL ONCOLOGY. SPRINGER.
- Patient perspectives on window of opportunity clinical trials in early-stage breast cancer.
  Parikh, D. A., Kody, L., Brain, S., Heditsian, D., Lee, V., Curtis, C., … Caswell-Jin, J. L. (2022). Patient perspectives on window of opportunity clinical trials in early-stage breast cancer. Breast Cancer Research and Treatment.
- Clinical Impact of Intraoperative Margin Assessment in Breast-Conserving Surgery With a Novel Pegulicianine Fluorescence-Guided System: A Nonrandomized Controlled Trial.
  Hwang, E. S., Beitsch, P., Blumencranz, P., Carr, D., Chagpar, A., Clark, L., … Smith, B. L. (2022). Clinical Impact of Intraoperative Margin Assessment in Breast-Conserving Surgery With a Novel Pegulicianine Fluorescence-Guided System: A Nonrandomized Controlled Trial. JAMA Surgery.
- The Clinical Impact of Intraoperative Margin Assessment in Breast Cancer Surgery using a Novel Pegulicianine Fluorescence Guided Surgery System: a Prospective Single Arm Study
  Hwang, S., Beitsch, P., Blumencranz, P., Carr, D., Chagpar, A., Clark, L., … Wapnir, I. (2022). The Clinical Impact of Intraoperative Margin Assessment in Breast Cancer Surgery using a Novel Pegulicianine Fluorescence Guided Surgery System: a Prospective Single Arm Study. ANNALS OF SURGICAL ONCOLOGY. SPRINGER.
- Multiomic analysis reveals conservation of cancer-associated fibroblast phenotypes across species and tissue of origin.
  Foster, D. S., Januszyk, M., Delitto, D., Yost, K. E., Griffin, M., Guo, J., … Longaker, M. T. (2022). Multiomic analysis reveals conservation of cancer-associated fibroblast phenotypes across species and tissue of origin. Cancer Cell.
- A Novel Fat-Augmented Omentum-Based Construct for Unilateral and Bilateral Free-Flap Breast Reconstruction in Underweight and Normal Weight Women Receiving Nipple or Skin-Sparing Mastectomies.
  Nguyen, D. H., Rochlin, D. H., Deptula, P. L., Zak, Y., Dua, M., & Wapnir, I. L. (2022). A Novel Fat-Augmented Omentum-Based Construct for Unilateral and Bilateral Free-Flap Breast Reconstruction in Underweight and Normal Weight Women Receiving Nipple or Skin-Sparing Mastectomies. Annals of Surgical Oncology.
- ASO Author Reflections: Innovation and the Development of a New Workhorse Flap in Breast Reconstruction.
  Nguyen, D. H., Rochlin, D. H., Deptula, P. L., Zak, Y., Dua, M., & Wapnir, I. L. (2023). ASO Author Reflections: Innovation and the Development of a New Workhorse Flap in Breast Reconstruction. Annals of Surgical Oncology.
- ASO Visual Abstract: A Novel Fat-Augmented Omentum-Based Construct for Unilateral and Bilateral Free Flap Breast Reconstruction in Underweight and Normal-Weight Women Receiving Nipple- or Skin-Sparing Mastectomies.
  Nguyen, D. H., Rochlin, D. H., Deptula, P. L., Zak, Y., Dua, M., & Wapnir, I. L. (2023). ASO Visual Abstract: A Novel Fat-Augmented Omentum-Based Construct for Unilateral and Bilateral Free Flap Breast Reconstruction in Underweight and Normal-Weight Women Receiving Nipple- or Skin-Sparing Mastectomies. Annals of Surgical Oncology.
- Nipple-areola-complex preservation and obesity-Successful in stages.
  Daly, L., Tsai, J., Stone, K., Wapnir, I., Karin, M., Wan, D., & Momeni, A. (2023). Nipple-areola-complex preservation and obesity-Successful in stages. Microsurgery.
- Intraoperative Fluorescence Guidance for Breast Cancer Lumpectomy Surgery
  Smith, B., & . (2023). Intraoperative Fluorescence Guidance for Breast Cancer Lumpectomy Surgery. New England Journal of Medicine Evidence.
- Correction: A Novel Fat-Augmented Omentum-Based Construct for Unilateral and Bilateral Free-Flap Breast Reconstruction in Underweight and Normal Weight Women Receiving Nipple or Skin-Sparing Mastectomies.
  Nguyen, D. H., Rochlin, D. H., Deptula, P. L., Zak, Y., Dua, M., & Wapnir, I. L. (2023). Correction: A Novel Fat-Augmented Omentum-Based Construct for Unilateral and Bilateral Free-Flap Breast Reconstruction in Underweight and Normal Weight Women Receiving Nipple or Skin-Sparing Mastectomies. Annals of Surgical Oncology.
- Frailty Analysis and Outcomes of Breast Cancer Surgery in Elderly Patients Aged 85 and Older
  Foulad, D., Wapnir, I., Xu, A., Stone, K., Dirbas, F., Karin, M., … Tsai, J. (2023). Frailty Analysis and Outcomes of Breast Cancer Surgery in Elderly Patients Aged 85 and Older. ANNALS OF SURGICAL ONCOLOGY. SPRINGER.
- Intraoperative Pegulicianine Fluorescence Guidance for Tumor Detection During Lumpectomy Surgery for Stage 0-III Breast Cancer
  Smith, B. L., Hunt, K. K., Carr, D., Blumencranz, P., Hwang, E. S., Gadd, M. A., … Wapnir, I. (2023). Intraoperative Pegulicianine Fluorescence Guidance for Tumor Detection During Lumpectomy Surgery for Stage 0-III Breast Cancer. ANNALS OF SURGICAL ONCOLOGY. SPRINGER.
- Mechanoresponsive Pancreatic Ductal Adenocarcinoma Cancer Associated Fibroblasts Shows an FAK-Dependent Subtype Divergent from Canonical Fibrotic TGFB-Pathway Dependence
  Foster, D., Delitto, D., Januszyk, M., Yost, K., Griffin, M., Guo, J., … Longaker, M. (2023). Mechanoresponsive Pancreatic Ductal Adenocarcinoma Cancer Associated Fibroblasts Shows an FAK-Dependent Subtype Divergent from Canonical Fibrotic TGFB-Pathway Dependence. ANNALS OF SURGICAL ONCOLOGY. SPRINGER.
- Age is Just a Number: A Single Institution Review of Surgical Management of Breast Cancer in Elderly Patients Aged 85 and Older
  Foulad, D. S., Tsai, J., Najafzadeh, P., Allison, K., & Wapnir, I. (2023). Age is Just a Number: A Single Institution Review of Surgical Management of Breast Cancer in Elderly Patients Aged 85 and Older. ANNALS OF SURGICAL ONCOLOGY. SPRINGER.
- Characteristics and Management of Breast Lesions in Elderly Patients Aged 85 and Older
  Foulad, D. S., Wapnir, I., Najafzadeh, P., Allison, K., & Tsai, J. (2023). Characteristics and Management of Breast Lesions in Elderly Patients Aged 85 and Older. ANNALS OF SURGICAL ONCOLOGY. SPRINGER.
- Influence of Imaging Features and Technique on US-guided Tattoo Ink Marking of Axillary Lymph Nodes Removed at Sentinel Lymph Node Biopsy in Women With Breast Cancer.
  Pajcini, M., Wapnir, I., Tsai, J., Edquilang, J., DeMartini, W., & Ikeda, D. (2021). Influence of Imaging Features and Technique on US-guided Tattoo Ink Marking of Axillary Lymph Nodes Removed at Sentinel Lymph Node Biopsy in Women With Breast Cancer. Journal of Breast Imaging, 3(5), 583–590.
- Positive pegulicianine fluorescence in the lumpectomy cavity correlates with tumor distance to margins
  Wapnir, I., Hwang, E. S., Hunt, K. K., Carr, D., Blumencranz, P., Smith, K. P., … Smith, B. (2024). Positive pegulicianine fluorescence in the lumpectomy cavity correlates with tumor distance to margins. ANNALS OF SURGICAL ONCOLOGY. SPRINGER.
- Patient Reported Outcomes from a multi-site, prospective Pivotal study evaluating pegulicianine fluorescence guided surgery (pFGS) for breast cancer lumpectomy procedures using the Lumicell Direct Visualization System (DVS)
  Hunt, K. K., Wapnir, I., Hwang, E. S., Carr, D., Blumencranz, P., Smith, K. P., … Smith, B. (2024). Patient Reported Outcomes from a multi-site, prospective Pivotal study evaluating pegulicianine fluorescence guided surgery (pFGS) for breast cancer lumpectomy procedures using the Lumicell Direct Visualization System (DVS). ANNALS OF SURGICAL ONCOLOGY. SPRINGER.
- Can Completion Axillary Lymph Node Dissection be Omitted after Neoadjuvant Endocrine Therapy?
  Beck, A. S., Troxell, M., Tsai, J., & Wapnir, I. (2024). Can Completion Axillary Lymph Node Dissection be Omitted after Neoadjuvant Endocrine Therapy? ANNALS OF SURGICAL ONCOLOGY. SPRINGER.
- Residual cancer burden in two-stage nipple sparing mastectomy after first stage lumpectomy and devascularization of the nipple areolar complex.
  Thompson, C. N., Chandler, J., Ju, T., Tsai, J., & Wapnir, I. (2024). Residual cancer burden in two-stage nipple sparing mastectomy after first stage lumpectomy and devascularization of the nipple areolar complex. Breast Cancer Research and Treatment.
- SCOUT Radar Localization at Time of Breast Biopsy.
  Dashevsky, B. Z., Muneer, M. S., Hao, M., Liang, T., Wapnir, I. L., & Poplack, S. P. (2024). SCOUT Radar Localization at Time of Breast Biopsy. Journal of Breast Imaging.

View More Publications

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Open Trials Closed Trials

Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer

Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer

Scintigraphic Assessment of I- Transport in Metastatic Breast Cancer and Evaluation of I31I Ablative Therapy: (Part I) Radioiodide Imaging Study

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

SPY Intra-Operative Angiography & Skin Perfusion in Immediate Breast Reconstruction w/ Implants

A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

Radioactive Iodide (131I) Treatment of 124I PET/CT Detected Breast Cancers

Factors Influencing Decision-Making About the Use of Chemoprevention in Women at Increased Risk for Breast Cancer

Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery

A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer

Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery

Pilot Indocyanine Green Imaging for Mapping of Arm Draining Lymphatics & Nodes in Breast Cancer

Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer

Intraoperative Detection of Residual Cancer in Breast Cancer

Investigation of Novel Surgical Imaging for Tumor Excision

Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC

Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer

LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy

Specializing In

Practice Locations

Stanford Women's Cancer Center Palo Alto, CA

Palo Alto, CA

Stanford Women's Cancer Center

900 Blake Wilbur Drive, 1st Floor

Palo Alto , CA 94304

(650) 498-6000

More Clinic Information

Breast Cancer Program in Palo Alto Palo Alto, CA

Palo Alto, CA

Breast Cancer Program in Palo Alto

900 Blake Wilbur Drive, 1st Floor

Palo Alto , CA 94304

(650) 498-6000

More Clinic Information

Important Information about Our Organizations and Physician Affiliation

Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.

Patient Ratings

(65 Ratings)

Overall Rating

4.7/5

View Ratings by Category

4.8/5

Friendliness

4.6/5

Explanations

4.7/5

Listens

4.7/5

Care provider's efforts to include you in decisions about your care

4.8/5

Recommended to others

0.0/5

Wait times

How Our Ratings Work

The Patients Ratings and comments are gathered from our Patient Satisfaction Survey and displayed in their entirety.

Patient Satisfaction Survey Disclaimer

Patient Reviews

(175 reviews)

I really appreciate Dr. Wapnir and feel she is very competent and knows her field of breast cancer very well. I am so glad I am able to have Dr. Wapnir as my physician

Sep 2024

•

Verified SHC Patient

She is a good Doctor

Sep 2024

•

Verified SHC Patient

I was very impressed with the coordination between the different doctors that I saw during my visit

Jul 2024

•

Verified SHC Patient

Very exceptional doctor!

Jun 2024

•

Verified SHC Patient

She is a great doctor. I wish I could clarify some of the questions I got after the video visit.

Apr 2024

•

Verified SHC Patient

Both doctors who saw me was very good. And clear with informations.

Mar 2024

•

Verified SHC Patient

I really appreciate Dr. Wapnir and feel very confident with her knowledge and care in my treatment. Thank you Dr Wapnir

Mar 2024

•

Verified SHC Patient

Dr Wapnir laid out several options then said we would pursue the one I wanted. I appreciated her seeking my wishes for my treatment.

Sep 2023

•

Verified SHC Patient

Everything was amazing and wonderful!

Aug 2023

•

Verified SHC Patient

Not rushed. Very thorough. Aubrey Ann , resident was comforting. Dr Wapnir has no room for improvement. She is really cut out for the work she does. Straightforward and skilled. Sensitive and supportive. I feel very confident in my treatment and the team approach . Very positive experience considering the heavy diagnosis.

May 2023

•

Verified SHC Patient

After being invited into exam room by a nurse on time of my appointment and answered a few questions from an in-residence doctor, I have waited in the exam room for almost an hour to see a doctor. She was brief and professional but didn't show any particular interest in my questions, referring me to another doctor. I understand it was not her particular area but my questions arose out of oncology concerns and she failed to address them. I left the appointment with no clear guidance

May 2023

•

Verified SHC Patient

Dr. Wapnir is very knowledgeable and genuinely cares about her patientâ€™s wellbeing and long-term health.

May 2023

•

Verified SHC Patient

Excellent care

Apr 2023

•

Verified SHC Patient

knowledgable, answered questions clearly, did not rush the appointment

Dec 2022

•

Verified SHC Patient

I have no doubt I am in the right place. I feel very good about the plan we have.

Nov 2022

•

Verified SHC Patient

Dr. Wapnir was very informative, knowledgeable and personable as well as NP, Victoria. They are A Good team!

Nov 2022

•

Verified SHC Patient

Very thorough and caring provider

Nov 2022

•

Verified SHC Patient

I really appreciated the nurse summarizing the medical speak. She spent all the time I needed to thoroughly understand my situation.

Oct 2022

•

Verified SHC Patient

They were very nice and helped me anything I need.

Oct 2022

•

Verified SHC Patient

Great friendly staff

Sep 2022

•

Verified SHC Patient

Dr Wapnir is a great doctor, very thoughtful and thorough.

Sep 2022

•

Verified SHC Patient

Dr Wapnir is an excellent surgeon and did exemplary work on my procedure. Very happy with it. I am confuse as was Dr Wapnir on how the tumor was missed in the left breast with the MRI. Hoping to find an answer to that question.

Aug 2022

•

Verified SHC Patient

Wonderful staff and very thorough

Aug 2022

•

Verified SHC Patient

Dr Wapnir is excellent in her care. She is a scientist and a great patient advocate. She is truly an expert in her field. She has done everything possible to provide the best care for me with my diagnosis .

Jul 2022

•

Verified SHC Patient

Iâ€™m very happy with Dr. Wapnir.

Jul 2022

•

Verified SHC Patient

Dr Wapnir is fantastic. She saved me.

May 2022

•

Verified SHC Patient

Very Calm and explained things slowly.

May 2022

•

Verified SHC Patient

Dr. Wapnir took the time to listen to my concern and provided information in a way i could understand. I definitely felt heard and left there feeling confident in my decision without any pressure.

Apr 2022

•

Verified SHC Patient

Dr Wapnir really cares about her patients.

Apr 2022

•

Verified SHC Patient

Wait time was too long. Was asked to change into a patient gown for no reason (physical exam was not needed at the follow up visit).

Apr 2022

•

Verified SHC Patient

Dr Wapnir and her team are exceptional.

Apr 2022

•

Verified SHC Patient

Very informative I was even given visual illustrations of what was explain to me it was awesome.

Apr 2022

•

Verified SHC Patient

Dr Wapnir is an excellent physician. She has patient's best interest at heart.

Mar 2022

•

Verified SHC Patient

She really care about her patients.

Mar 2022

•

Verified SHC Patient

Dr. Wapnir is a very skilled and an awesome surgeon. As a patient I've seen and believe that she has my best interest at all times. I felt sad and happy when I was told I no longer don't need to see her. I am truly thankful with the care and expertise that she provided for me.

Mar 2022

•

Verified SHC Patient

I found Dr. Wapnir to be very kind and also rather brutally honest which is what I was asking for so my impression is that Dr. Wapnir really tries to understand her patients.

Mar 2022

•

Verified SHC Patient

The staff, including Dr Wapnir was very kind,caring and informative.

Feb 2022

•

Verified SHC Patient

Wait time indicator in waiting room was not accurate, but doctor was excellent

Feb 2022

•

Verified SHC Patient

OK!

Jan 2022

•

Verified SHC Patient

Thank you!

Jan 2022

•

Verified SHC Patient

Dr. Wapnir is very attentive and takes the time to answer all of my questions.

Dec 2021

•

Verified SHC Patient

Excellent!!!

Dec 2021

•

Verified SHC Patient

Dr.Wapnir rocks she is the best!

Dec 2021

•

Verified SHC Patient

Knowledgeable and caring.

Dec 2021

•

Verified SHC Patient

Excellent doctor: expertise in her field; well-trained and compassionate physician.

Dec 2021

•

Verified SHC Patient

Stanford is the BEST once you get a doctor.

Nov 2021

•

Verified SHC Patient

Dr. Wapnir is excellent. She is professional, caring, and listens to her patient.

Oct 2021

•

Verified SHC Patient

Dr. Wapnir is an excellent breast surgeon.

Aug 2021

•

Verified SHC Patient

Dr. Wapnir is the reason that I go to Stanford. She is personable, most knowledgeable, listens to any issues or questions that one has.

Aug 2021

•

Verified SHC Patient

Appreciate her thorough approach to surgery preparation and willingness to consider and counsel me on cosmetic results as well as removal of the disease.

Aug 2021

•

Verified SHC Patient

I did not find Dr. Wapnir very warm or welcoming and I will be requesting to see another provider.

Jul 2021

•

Verified SHC Patient

I have experienced Very engaged doctors and team members

Jul 2021

•

Verified SHC Patient

Dr. Wapnir is highly regarded and very knowledgeable in her field. Also, very respectful and relates extremely well with her patients. Her Resident, Dr. Ju, equally learning from the best.

Jul 2021

•

Verified SHC Patient

She is practical, forthright but listens to question and answers straight forwardly. I wouldn't say she is overly warm and friendly but she is not rude or abrupt

Jun 2021

•

Verified SHC Patient

I hope that Dr. Wapnir is amazing at performing surgeries to make up for her lack of skills in interacting with patients.

Jun 2021

•

Verified SHC Patient

Terrific knowledge and dedication. Dr. Wapnir was very thorough and helped me reach a decision I am comfortable with.

Jun 2021

•

Verified SHC Patient

Good.

Apr 2021

•

Verified SHC Patient

Dr. Wapnir shows an intellectual as well as an emotional concern for her patients. She is an excellent surgeon.

Mar 2021

•

Verified SHC Patient

First visit.

Mar 2021

•

Verified SHC Patient

Dr. Wapnir is always nice and very sensitive to my feelings. It was an unfortunate circumstance to meet her, but I'm glad to getting to know Dr. W.

Mar 2021

•

Verified SHC Patient

Dr. Wapnir has lots of knowledge in his profession. Great kindness and respect.

Feb 2021

•

Verified SHC Patient

Dr. Wapnir & Residents were clear about what to expect, professional and did an outstanding job communicating options, what to expect etc...

Jan 2021

•

Verified SHC Patient

Actually - No problems!

Jan 2021

•

Verified SHC Patient

Dr. Wapnir is the reason I continue to use Stanford Breast Center. She is professional, informative honest - listens to my questions and concerns.

Oct 2020

•

Verified SHC Patient

My experience w/Dr. Wapnir has been excellent as well as w/her medical assistant.

Oct 2020

•

Verified SHC Patient

LOVE Dr. Wapnir - direct, clear, thorough, professional. Met Dr. Momeni - who explained procedures in incredible detail.

Sep 2020

•

Verified SHC Patient

Everyone is very nice and friendly and in good manner also.

Jun 2020

•

Verified SHC Patient

Poor body language undermined previous practitioners, seemed annoyed or disinterested, yet narcissistic.

May 2020

•

Verified SHC Patient

She dr. was not polite when asking a question of a follow up procedure. She raised her voice.

Mar 2020

•

Verified SHC Patient

Dr. Wapnir is extraordinary. I feel lucky to have her as my surgeon.

Mar 2020

•

Verified SHC Patient

Outstanding in every area. BRAVO STANFORD!!!

Feb 2020

•

Verified SHC Patient

Dr. Wapnir was honest & clean in presenting the situation. I appreciated that.

Feb 2020

•

Verified SHC Patient

Dr. Wapnir ALWAYS caring & compassionate!

Feb 2020

•

Verified SHC Patient

Excellent surgeon.

Oct 2019

•

Verified SHC Patient

Dr. Wapnir & staff were professional they never rushed through my appointment and answered all my questions in detail.

Oct 2019

•

Verified SHC Patient

Dr. Wapnir is the reason I go to Stanford Medical. I have all the confidence in the world in her. She is one of the best doctors I have ever been to.

Sep 2019

•

Verified SHC Patient

Dr. Wapnir is GREAT!!! She saved my life... 18 yr. breast cancer survivor! We have a wonderful doctor/patient relationship. My husband comes to my appts. and Dr. Wapnir & him have a good relationship.

Aug 2019

•

Verified SHC Patient

I thank God for Stanford and Dr. Wapnir. She is OUTSTANDING.

Aug 2019

•

Verified SHC Patient

Great care provided for me.

Jul 2019

•

Verified SHC Patient

Best I've ever had out of all hosp. (CMPC, UCSF) Marin Gen.

Jul 2019

•

Verified SHC Patient

Dr. Wapnir is outstanding. she is caring, supportive, knowledgeable and the best physician I've had the pleasure to work with. I trust her completely.

Jun 2019

•

Verified SHC Patient

The doctors & staff were excellent.

Jun 2019

•

Verified SHC Patient

Dr. Wapnir is extraordinary in surgical treatment and the human touch.

May 2019

•

Verified SHC Patient

Dr. Wapnir is amazing!

May 2019

•

Verified SHC Patient

Dr. Wapnir is a great surgeon. As long as I'm living I am very thankful. I could tell she is a strong & confident surgeon which is what I needed. If she is a coffee, she is an espresso with a naturally occurring sugar.

Apr 2019

•

Verified SHC Patient

Dr. Wapnir is excellent. I would recommend her to anyone needing breast surgery.

Feb 2019

•

Verified SHC Patient

Dr. Wapnir was so helpful and professional. I had other doctors tell me horror stories or belittle me before. Dr. Wapnir is wonderful.

Jan 2019

•

Verified SHC Patient

Dr. Wapnir was perfect for me. She was a mix of care & honesty/truth. She's not particularly warm & fuzzy, but I had complete confidence in her & felt she always had my health, happiness & best interests in mind. I trusted her & could feel her competence.

Dec 2018

•

Verified SHC Patient

Excellent attention! Thanks!

Dec 2018

•

Verified SHC Patient

I did not get pertinent information about my condition and and explanation for the best care going forward, I feel very sad about this experience.

Oct 2018

•

Verified SHC Patient

Main reason I'm there is taking part in Dr. Telli's study and she sees me every time. She is one of the best dr. a patient expects.

Aug 2018

•

Verified SHC Patient

I've had surgery done by Dr. Wapnir twice in 12 years and find her to be an exacting, conscientious, and scrupulous surgeon, always informative, yet always caring and personable. What more could one ask!

Jul 2018

•

Verified SHC Patient

Very good.

Jul 2018

•

Verified SHC Patient

In the 2 1/2 years since my diagnosis of cancer, Dr. Wapnir is hands down the best oncological breast surgeon I have seen to date.

Jun 2018

•

Verified SHC Patient

Was actually scheduled with a different provider. Dr. Wapnir made time (unscheduled) for a consultation with me. Very impressed with all personnel.

May 2018

•

Verified SHC Patient

Dr. Wapnir is the reason I drive 100 miles for my medical attention. There is a closer breast clinic/hospital 5 miles from my home, but I choose Dr. Wapnir.

May 2018

•

Verified SHC Patient

Dr. Wapnir is thorough, careful and has common sense, often lacking in Stanford docs, and much to be applauded.

May 2018

•

Verified SHC Patient

Dr. Wapnir is truly a fabulous physician. She is kind, patient, informative and an outstanding listener which is incredibly appreciated. Stanford is lucky to have her!!

Apr 2018

•

Verified SHC Patient

Dr. Wapnir has always provided me with the best care - answered my questions and advised me - I have the utmost respect and gratitude for and to this wonderful woman.

Mar 2018

•

Verified SHC Patient

A very compassionate dr.

Feb 2018

•

Verified SHC Patient

Good - very competent staff.

Oct 2017

•

Verified SHC Patient

She is the best there is. Always caring & friendly.

Aug 2017

•

Verified SHC Patient

Dr. Wapnir devotes time to details/she is always so comforting.

Jul 2017

•

Verified SHC Patient

Dr. Wapnir is amazing - I would (and have) recommended her to others wholeheartedly.

Jul 2017

•

Verified SHC Patient

Dr. Irene Wapnir is the best dr. I have had my whole life.

Jul 2017

•

Verified SHC Patient

I left more confused than when I arrived & dr. seemed dismissive to my concerns. She pushed her own agenda & didn't listen to me.

Jun 2017

•

Verified SHC Patient

Wapnir always has time to answer all questions and is genuinely concerned with my care and outcome.

Apr 2017

•

Verified SHC Patient

Very much appreciate being fit in through Dr. Wapnirhad a surgery to get to.

Apr 2017

•

Verified SHC Patient

All my visits have been excellent thanks to all of Doctor Wapnir, Irene Leonor's team.

Apr 2017

•

Verified SHC Patient

She confused me, didn't answer my questions & was very dismissive I'll be cancelling my follow up visit & pursuing another physician.

Mar 2017

•

Verified SHC Patient

Dr. Wapnir & I go way back. I was one of her first patients. She has taken excellent care of me over the last 16 yrs. She saved my life!

Feb 2017

•

Verified SHC Patient

Dr. Wapnir is outstanding in every way.

Feb 2017

•

Verified SHC Patient

Irene is the BEST! She knows her staff and she is a great advocate for the patient!

Feb 2017

•

Verified SHC Patient

Dr. Wapnir is the best. Very glad I went to Stanford Cancer Center.

Feb 2017

•

Verified SHC Patient

Dr. Wapnir either doesn't talk to me or walk in and walk out with me or two sentences. She leave me with her assistance for all examination and discussion.

Jan 2017

•

Verified SHC Patient

I've never had a bad experience at Stanford Health Care.

Jan 2017

•

Verified SHC Patient

Very pleased with interactions with all providers I had contact with.

Dec 2016

•

Verified SHC Patient

Good.

Dec 2016

•

Verified SHC Patient

I have a long history with Dr. Wapnir and trust her with my life.

Dec 2016

•

Verified SHC Patient

The best!

Dec 2016

•

Verified SHC Patient

Dr. Wapnir is the BEST! I would not consider going to anyone else. I love her!

Nov 2016

•

Verified SHC Patient

The best!!

Nov 2016

•

Verified SHC Patient

She is a very busy doctor but spends her time efficiently with her patient!!

Nov 2016

•

Verified SHC Patient

I appreciate that Dr. Wapnir follows up on her patients, herself - It is the reason I drive to Stanford from Fremont. Kerry Shefren, NP who works with Dr. Wapnir is also excellent.

Oct 2016

•

Verified SHC Patient

Dr. Wapnir went out of her way to ease my concerns due to a lump I had. She rushed my mammo & U. sound up so I wouldn't need to wait a month. Very blessed to have her.

Oct 2016

•

Verified SHC Patient

I am very pleased with Dr Irene Wapnir and her colleagues. Each of the individuals I dealt with were exceptional from the Med Tech, her Nurse, Nurse Practitioner and of course, Dr. Wapnir.

Oct 2016

•

Verified SHC Patient

The Doctor Wapnir spent few time with me. Gave me impression that her time is valuable and don't want to spend them with me. All communication is her assistant who is nice and patient.

Sep 2016

•

Verified SHC Patient

Provider again was clear & thorough, we were able to ask questions, explained everything. Left freely very good & now we would be taken care of.

Sep 2016

•

Verified SHC Patient

Dr. Wapnir is the reason I go to Stanford. I have full confidence in anything Dr. Wapnir recommends. Her knowledge and understanding of our conditions and concerns is well above any other doctor.

Sep 2016

•

Verified SHC Patient

Excellent help-wonderful surgeon!

Aug 2016

•

Verified SHC Patient

Experience was great, would of liked just a bit more time explaining type tumor. But was REASSURING to me same "plan" would continue.

Aug 2016

•

Verified SHC Patient

I always have and exceptionally good experience with Dr. Wapnir.

Aug 2016

•

Verified SHC Patient

I would have liked a little bit more time with Dr. Wapnir before other members entered the room (more one on one explanations).

May 2016

•

Verified SHC Patient

Because of the trust & confidence I have in Dr. Wapris, the problems that I am face are surmountable.

May 2016

•

Verified SHC Patient

Dr. Wapnir and has her physician (cardiac) assistant were wonderful.

May 2016

•

Verified SHC Patient

The physician assistant and Doctor were excellent and very caring. They answered all my questions and made me at ease and comfortable. I would recommend them.

May 2016

•

Verified SHC Patient

I was made to feel so much more comfortable with my situation & Dr. Wagner & Telli went out of their way to help me! I am grateful to both of them.

Apr 2016

•

Verified SHC Patient

We could not believe the time she spent with us it was as though she had no other patient that day - amazing to feel that way as a patient.

Apr 2016

•

Verified SHC Patient

Dr. Wapnir is an outstanding doctor. I have recommended her to many others and they all love her too....they thank me for giving them her name. Dr. Wapnir has so much knowledge and uses it to help you with your treatment plan and things are always done in a timely fashion - she can make things happen!! Her PA Candice is wonderful and so is Jackie that is also in her department. I am very blessed that God led me to Dr. Wapnir.

Mar 2016

•

Verified SHC Patient

They were very good I am very appreciative with the care & treatment of everyone.

Mar 2016

•

Verified SHC Patient

Dr. Wapnir was in a hurry. Was somewhat abrupt with me. Looked in cabinet for cytology supplies, but when not found, didn't both to get from somewhere else, so nipple discharge wasn't sent to lab. Was short with me & a bit demeaning when I asked about HRT.

Mar 2016

•

Verified SHC Patient

I highly recommend to my friend and to all my relations about Stanford.

Mar 2016

•

Verified SHC Patient

Dr. Wapnir saved my life! I am almost 15 years cancer free!!

Feb 2016

•

Verified SHC Patient

Both Dr. & PA were a bad experience.

Feb 2016

•

Verified SHC Patient

Highly recommended!

Feb 2016

•

Verified SHC Patient

I can not praise Dr. Wapnir & her medical staff enough! Wonderful! Thank you much!!

Feb 2016

•

Verified SHC Patient

Kerry Shefren NP, was very professional and caring. Dr. Wapnir was outstanding. I felt very comfortable in their hands!

Feb 2016

•

Verified SHC Patient

I have the highest confidence in Dr. Wapnir professional judgment and value her care and concern.

Feb 2016

•

Verified SHC Patient

Dr. Wapnir is the best!!

Feb 2016

•

Verified SHC Patient

Dr. Wapnir is an amazing doctor & woman. Her staff is also wonderful.

Jan 2016

•

Verified SHC Patient

Dr. Wapnir & her PA are both outstanding. They are competent, responsive and extremely caring.

Jan 2016

•

Verified SHC Patient

Good rather than very good - answers to some questions skillfully avoided.

Jan 2016

•

Verified SHC Patient

I recommended Dr. Wapnir for my daughter.

Jan 2016

•

Verified SHC Patient

Dr. Wapnir - she is wonderful - a great surgeon AND spent needed time with me explaining the best path for me - Cannot praise our work & efforts enough!

Dec 2015

•

Verified SHC Patient

Jenny & Jenn-Marie are warm, caring people who make me feel like my well-fare is a top priority!

Nov 2015

•

Verified SHC Patient

I didn't feel like Dr. Wapnir had much time for me.

Nov 2015

•

Verified SHC Patient

The provider did not ask what my goals were for my treatment. She assumed that I value what she values and that is not the case -

Sep 2015

•

Verified SHC Patient

She is great ,i can not ask for more

Sep 2015

•

Verified SHC Patient

I previously commented about Dr. Irene Wapnir in this survey. I think she provides exceptional care to her patients, and she instills confidence in my to continue my care with her at Stanford.

Jul 2015

•

Verified SHC Patient

I came in sick - a non-breast issue. Dr. Wapnir brought in someone to help me with my problem.

Jun 2015

•

Verified SHC Patient

I have had years of excellent care.

Apr 2015

•

Verified SHC Patient

All good.

Apr 2015

•

Verified SHC Patient

Dr. Wapnir is fantastic!! She along with Dr. Carlson & the staff at Stanford saved my life. I am a 13 yr breast cancer survivor thanks to them!

Jan 2015

•

Verified SHC Patient

I have already been praising my experience to anyone with health issues.

Dec 2014

•

Verified SHC Patient

Already recommended Dr. Wapnir to all my sisters and friends. We love Dr. Wapnir. I donate to Stanford every year because of her excellent care -

Dec 2014

•

Verified SHC Patient

I'm pleased w/my dr. except I would like a phone call after my blood tests.

Nov 2014

•

Verified SHC Patient

Good.

Oct 2014

•

Verified SHC Patient

I have complete confidence in Dr. Wapnir. My experience with Stanford Breast Center has been outstanding.

Sep 2014

•

Verified SHC Patient

I felt that Dr. Wapnir really listened to me and thoroughly explained potential next steps.

Jun 2014

•

Verified SHC Patient

She seemed to genuinely care about me/her patients, but seemed to have an agenda around her preferred treatment/studies.

May 2014

•

Verified SHC Patient

Dr. Irene Wapnir is an extraordinary doctor, highly professional caring, attentive, and knowledgeable.

Apr 2014

•

Verified SHC Patient

Dr. Wapnir is the BEST.

Apr 2014

•

Verified SHC Patient

Response to all questions after the appt. was very prompt.

Mar 2014

•

Verified SHC Patient

Excellent surgeon, but just "OK" bedside manner.

Feb 2014

•

Verified SHC Patient

I love Dr. Wapnir. She is very nice to me.

Feb 2014

•

Verified SHC Patient

View More Patient Reviews

Referring Physicians

PHYSICIAN HELPLINE

Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.

Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.

You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.

Send referrals online
Place radiology and lab orders
View referral status
Access medical records

Learn More About MedLink

LOG INTO MEDLINK

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

Irene Wapnir, MD

Surgical oncologist, Breast surgeon, Breast specialist

Get In Touch

Biography

Professional Summary

Education & Certifications

Honors & Awards

Memberships

Administrative Appointments

Publications

Clinical Trials

Specializing In

Practice Locations

Stanford Women's Cancer Center Palo Alto, CA

Stanford Women's Cancer Center

Breast Cancer Program in Palo Alto Palo Alto, CA

Breast Cancer Program in Palo Alto

Important Information about Our Organizations and Physician Affiliation

Patient Ratings

How Our Ratings Work

Patient Reviews

(175 reviews)

Referring Physicians

PHYSICIAN HELPLINE

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

WELCOME BACK

Irene Wapnir, MD

Surgical oncologist, Breast surgeon, Breast specialist

Get In Touch

Biography

Professional Summary

Education & Certifications

Honors & Awards

Memberships

Administrative Appointments

Publications

Clinical Trials

Specializing In

Practice Locations

Stanford Women's Cancer Center Palo Alto, CA

Stanford Women's Cancer Center

Breast Cancer Program in Palo Alto Palo Alto, CA

Breast Cancer Program in Palo Alto

Important Information about Our Organizations and Physician Affiliation

Patient Ratings

How Our Ratings Work

Patient Reviews

(175 reviews)

Referring Physicians

PHYSICIAN HELPLINE